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Regulation of blood glucose levels is of paramount importance to human physiology. 
Normally, blood glucose level is tightly regulated as a part of metabolic homeostasis. When 
blood glucose falls below a certain level, the body starts to use stored sugar as an energy 
source through glycogenolysis, and converses stored glycogen in the liver and muscle to 
glucose, which can then be utilized as an energy source. Conversely, when blood glucose 
exceeds the normal level, the excess glucose (which otherwise would be toxic) is removed 
from the blood by the action of insulin, a peptide hormone produced by beta-cells of the 
pancreas. Key mechanisms dispatching the action of insulin consist of the promotion of the 
uptake of glucose in skeletal muscle and fat tissue and of shifting metabolism towards fat 
storage rather than fat utilization for energy. 
When regulatory mechanisms fail to adequately maintain blood glucose within the normal 
range, conditions of abnormally diminished (hypoglycemia) or excessive (hyperglycemia) 
blood glucose levels occur producing a variety of symptoms. Hypoglycemic symptoms and 
manifestations are related to the actions produced by counter regulatory hormones 
(adrenaline and glucagon) triggered by the falling glucose level (e.g. shakiness, anxiety, 
tachycardia, sweating, hunger, nausea, headache, etc.), and the neuroglycopenic effects by 
the reduced brain glucose level (e.g. mental abnormalities and personality change, fatigue, 
weakness, blurred/double vision, lack of coordination, etc.). Brain effects can range from 
mild dysphoria to serious seizures and unconsciousness. In contrast, when temporary, 
hyperglycemia is often benign and asymptomatic. Blood glucose levels can rise well above 
normal for significant periods without producing any obvious effects or symptoms. 
However, chronic hyperglycemia at levels more than slightly above normal may produce a 
wide variety of serious complications over a period of years. When the glucose 
concentration in the blood remains high over time, the kidneys will reach a threshold of 
reabsorption, and glucose will be excreted in the urine (glycosuria). This increases the 
osmotic pressure of the urine and inhibits reabsorption of water by the kidney, resulting in 
increased urine production and increased fluid loss. The decrease in blood volume is 
compensated by water held in body cells and other body compartments, causing 
dehydration and thirst. Consequently, the classical symptoms of hyperglycemia, next to 
polyphagia, are polydipsia and polyuria. 



























Chronic hyperglycemia that persists even during fasting defines a state referred to as 
diabetes mellitus (DM). DM is due to insufficient production of insulin by the pancreas, or 
by insensitivity of body cells to the action of insulin. There are three main types of DM. (i) 
Type 1 diabetes mellitus (T1DM) results from the body's failure to produce sufficient 
amounts of insulin, the cause of which is unknown. This form was previously referred to as 
"insulin-dependent diabetes mellitus" (IDDM) or "juvenile diabetes". (ii) Type 2 diabetes 
mellitus (T2DM) starts with a condition in which cells fail to respond to insulin properly, 
termed "insulin-resistance". As the disease progresses insufficient production of insulin 
may also develop due to beta cell exhaustion. This form was previously referred to as "non-
insulin-dependent diabetes mellitus" (NIDDM) or "adult-onset diabetes". (iii) Gestational 
diabetes is the third main form occurring in pregnant women, who develop increased levels 
of blood glucose without a previous history of diabetes. During pregnancy, the placenta, 
which connects baby to mother blood supply, produces high levels of various hormones 
which impair the action of insulin in the mother. Gestational diabetes usually develops 
during the second half of pregnancy. 
Trends in obesity, metabolic syndrome and T2DM leading to cardiovascular disease 
In 2011, according to International Diabetes Federation, an estimated 366 million people 
word wide had diabetes, with type 2 making up the majority of the cases. Its prevalence is 
increasing rapidly and is estimated to be almost doubled by 2030 [1]. Diabetes occurs 
throughout the world, but is more common (especially type 2) in the more developed 
countries. However, the largest increase in prevalence is expected to occur in Africa, where 
the incidence is predicted to be amongst the highest by 2030 [2]. The increase in incidence 
in developing countries follows the trend of urbanization and lifestyle changes, perhaps 
most importantly a "Western-style" diet. This has suggested an environmental (i.e., dietary) 
effect although there is little understanding of the mechanism(s) at present. However, 
striking similarities have been observed between epidemic increases in overweight and 
obesity with the profound increases in DM in recent decades. Overweight goes hand in 
hand with the development of T2DM. People who are overweight are at much greater risk 
of developing T2DM than individuals with normal weight. In fact, obesity is at the 
background of the risk of developing T2DM [3]. 
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It is well known that obesity commonly coexist with insulin resistance, although causal 
links between insulin resistance, obesity, and dietary factors are complex and controversial 
[3]. It is possible that one of them arises first, and tends to cause the other; or that insulin 
resistance and excess body weight might arise independently as a consequence of a third 
factor, but end up reinforcing each other. Some population groups might be genetically 
predisposed to one or the other. Central obesity is the principal symptom of what is referred 
to as "metabolic syndrome" (MetS), a disorder of energy utilization and storage also known 
as (metabolic) syndrome X, cardiometabolic syndrome and Reaven's syndrome, amongst 
others. MetS is diagnosed by a co-occurrence of three out of five of the following medical 
conditions: abdominal (central) obesity, elevated blood pressure, elevated fasting plasma 
glucose, high serum triglycerides, and low high-density cholesterol (HDL) levels [4]. Risk 
factors of MetS include, but may not be restricted to, stress, overweight and obesity, 
sedentary lifestyle, Western dietary pattern, hyperphagia and ageing. 
Crucially, however, MetS markedly increases the risk of developing DM and 
cardiovascular disease (CVD). MetS and DM are associated with dyslipidemia which is 
also a risk factor for CVD. Dyslipidemia is associated with impaired carotid artery 
elasticity, intima-media thickness and brachial flow-mediated dilatation [5]. Atherosclerotic 
plaque is associated with the elevation of non-high density lipoprotein cholesterol [6]. As 
dyslipidemia develops the number of risk factors and severity of asymptomatic coronary 
and aortic atherosclerosis increases. In addition, DM itself is suggested to be an 
inflammatory disease and important risk factor for CVD as statistics indicate a strong 
correlation between CVD and DM. Hence, adults with DM are more likely to have heart 
disease or stroke than adults without DM [7]. Heart diseases and stroke actually are the 
number 1 causes of death and disability among people with T2DM. In fact, a considerable 
percentage of people with DM do not die of DM itself but of some form of hypertension, 
heart disease or stroke! [7]. As highlighted later on in this thesis, we believe that this 
importantly involves the effect of DM attenuating vascular function. 
 
The diabetes epidemic is an epidemic of diabetic micro- and macrovascular 
complications 



























In the United States alone, nearly 174 million people have undiagnosed DM, as delineated 
from over 744 reviewed data sources [8], but at the same time are at great risk to develop 
end-organ damage and die from CVD. There is consensus that key to the increased 
mortality are the changes in micro- and microvasculature. 
Atherosclerosis is a main consequence of macrovascular disease in DM. Narrowing and 
stiffing of arterial walls throughout the body - which is formed by the build-up of fats, 
cholesterol and other substances in and on the arteries walls (plaques) - can restrict blood 
flow. These plaques may burst and trigger the formation of blood clots and heart problems 
[9,10]. 
People with DM may experience damage to micro vessels and nerves, e.g. in the back of 
the eye leading to diabetic retinopathy, a condition of eye problems that may include 
reduced vision [11]. Indeed, DM is the main cause of acquired blindness in people under 
the age of 65 and is one of the leading causes in older adults. DM may also cause damage 
to micro vessels in the kidney leading to diabetic nephropathy and the attenuation of kidney 
structure and function. This can progress to a devastating disease: kidney failure. Treatment 
of kidney failure requires dialysis or transplantation. These procedures are a burden to 
patients and society. Hence, DM is the main reason for Americans to be dialyzed. 
Furthermore, chronic kidney disease per se is a risk factor for CVD thereby further 
contributing to the high incidence of cardiovascular mortality in DM [12,13]. 
Diabetes also may damage the peripheral nervous system innervating the arms and legs. 
Affected patients experience pain, and tingling or buzzing sensations in their hands and/or 
feet. Patients may lose bladder control, or the ability to walk, and males show loss of ability 
to function sexually (impotence or erectile dysfunction) [14]. Other complications of DM 
include diabetic dermopathy and cognitive disturbances. Nevertheless, the majority of DM 




Figure 1. By increasing metabolic syndrome and diabetic mellitus, the complications of micro- and macro-
vascular dysfunction and end-organ damage raises significantly. 
 
Prevention and treatment of diabetes: current measures and limitations 
The above may be summarized in a scheme of conditions in which micro- and 
macrovascular disease associated with or resulting from DM leads to development of end-
organ damage and death from CVD: see Figure 1. Of note in this scheme are the initial 
conditions in MetS which precede and feed the development of DM, and the notion that 
initial overweight/obesity at the start of the scheme currently is a growing global issue 
reaching epidemic proportions. The consequence hereof is a threatening revival of 
premature CVD-morbidity and -mortality worldwide, and an associated rise in economic 
(health care) costs. The current diabetes treatments indeed improved general complications 



























but still not enough to halted and reversed the complications of CVD-events. Hence, to 
improve diabetes outcome nowadays necessitates both the prevention of (epidemic) DM2 
and development of adequate strategies coping with its consequences. 
The main measure to prevent development of DM consists of life-style changing measures 
to prevent initial conditions (of MetS) leading hereto (Figure 2). These consist of changing 
a diabetic prone lifestyle such as decreased physical activity and replacing the ‘Western 
type diet’ of high fat food, refined sugar and excessive processed red meat with a high fiber 
and green diet. In addition, proper pharmacological treatments are needed to control the 
condition of per se DM and its consequences: the anti-diabetic drugs (Figure 2). Current 
pharmacological interventions that have been developed in recent years are aimed at 
controlling plasma glucose levels either by inhibition of gluconeogenesis or increasing the 
levels of insulin or improving the body's sensitivity to insulin. Nowadays a range of anti-
diabetic medicines are clinically available, including insulin, sulfonylureas, disaccharidase 
inhibitors, thiazolidinediones, meglitinides, GLP analogs, amylin analogs and DPP-IV 
inhibitors which can be used alone or in combination of together [15]. 
Unfortunately, the effectiveness of lifestyle changes to prevent DM are not always 
successful. This may be due both to poor compliance but also a lack of knowledge 
regarding specific gene-environment interactions that predispose to DM. Hence, we do not 
always know which individuals are more at risk of developing DM as compared to others, 
meaning that "standard" lifestyle changing programs may "work" for some in the general 
population but not all. Such programs could be more successful when focused on (groups 
of) individuals who are more likely (i.e. at risk) to enter the obesity-MetS-DM sequel or 
suffer its consequences to a higher extent (i.e. a higher degree of mirco- and macrovascular 
disease and end-organ damage than others). Such (groups of) individuals could be more 
specifically targeted at an earlier stage, were it not that these individuals are insufficiently 
identified at present. 
In a similar way, not all of the currently available anti-diabetic drugs actually are successful 
in all DM patients. Some anti-diabetic drugs seem to provide less CVD-benefit than would 
be expected based on their ability for glycemic control. Vice versa, other treatments seem 
to provide protection against end-organ damage in DM that goes beyond glycemic control, 




Figure 2. Current measures to prevent diabetes include a change in sedentary life-style and dietary patterns next to 
the anti-diabetic treatments that aim to control hyperglycemia. 
 
A chance for innovative targets and therapies 
Thus besides (1) preventing diabetes and (2) treating its symptoms, discomforts and life-
threats directly associated with hyperglycemia as in current approaches, additional 
important goals include (3) a better identification of (groups of) individuals who are at 
higher risk of developing DM or more severely suffering its consequences and (4) the per 
se prevention of end-organ damage in DM.  
(ad.3) Individual susceptibility to end-organ damage is largely variable anyhow, even 
among seemingly similar (normal healthy) individuals. The possibility to identify those 



























individuals who are at a risk of developing a higher degree of end-organ damage when DM 
develops would provide additional options for 'personalized medicine' at an early stage. 
Variability in vascular function among subjects at apparent normal health could be such an 
identifier of an individual's susceptibility to end-organ damage but this has not yet been 
studied in subjects prone to develop MetS and DM. If so, however, vascular function would 
be an important pharmacological target, both in pre-DM (i.e. to reduce initial susceptibility 
to end-organ damage in DM) and in DM-conditions (i.e. to inhibit the progression of 
existing end-organ damage). 
(ad.4) The per se prevention of end-organ damage in DM further implies that a potential 
direct protective (i.e. pleiotropic) effect of an anti-diabetic compound against end-organ 
damage is as relevant as its property (by definition) to control hyperglycemia. Such effects 
may include actions on yet unidentified targets but which bear significant relevance to end-
organ damage in DM. Taken together, the above provides relevant opportunities for 
innovative new targets and therapies, as summarized in Figure 3. 
Chapter 1 
 18 
Figure 3. Maintaining the integrity of vascular function can should be considered an important target for MetS and 
DM treatment. 
 
Targets and treatments explored in this thesis 
The aim of this thesis was to explore new targets and therapies to prevent end-organ 
damage in diabetes. To this end we focused on: 
1. vascular function as a predictor of individual susceptibility to end-organ damage in 
subjects prone to develop DM, 
2. key mechanisms of end-organ damage in DM as potential new targets of therapy, 
3. pleiotropic vascular/hemodynamic effects of existing anti-diabetic agents and 
promising non anti-diabetic agents.  
 



























Ad.1 To address the above we first employed the obese Zucker diabetic fatty rat (ZDF) 
model of end-organ injury and function loss in DM in Chapters 2 and 3. In Chapter 2 the 
aim was to study the predictive value of intra-organ vessel function for an (normal?) 
individual's susceptibility to develop end-organ damage in DM. To this end, intra-renal 
vascular function was assessed in young ZDF when still at pre-diabetic state and without 
renal damage. Individuals were then followed over time for urinary protein excretion and 
glomerulosclerosis as indices of renal injury during DM development, and correlated this 
with intra-renal artery function at baseline.  
Ad.2 The ZDF model was also used for the studies of brain damage in DM. Protein 
aggregate formation is a common feature of neurodegenerative diseases leading to 
neurofibrillary tangle formation with cognitive deficits. In Chapter 3, we studied the 
presence of protein aggregation in the frontal brain of ZDF with aim to identify key 
mechanistic targets. Given their roles in proteostasis and brain anti-oxidant formation, 
respectively, we focused on the mTOR-pathway and H2S producing enzyme cystathionine 
beta synthase (CBS). 
Ad.3 Endothelial dysfunction has emerged as a target for primary prevention strategies in 
CVD. It has been suggested that certain anti-diabetic drugs - e.g. metformin - provide 
cardiovascular benefit beyond glycemia control, possibly via a (glucose-independent) direct 
effect on vascular function. In Chapter 4 we used spontaneously hypertensive rats (SHR) - 
a model of endothelial dysfunction in a setting of HT - to further investigate this. 
Endothelium-dependent relaxation was studied in aortas of SHR with and without 
streptozotocin-induced type 1 DM (T1DM) after long-term treatment with metformin or 
vildagliptin. Finally in Chapter 5 we studied the vascular treatment effects of FTY720 
(fingolimod). Interest in this novel immunomodulator for treatment of T1DM has increased 
recently. FTY720 suppresses the immune response by sequestering circulating mature 
lymphocytes from the blood and peripheral tissues to secondary lymphoid tissues and the 
thymus. It has been suggested that similar mechanisms may help to protect islet beta cells 
from autoimmune destruction at an early stage of DM. First results in animal studies are 
promising but whether this might involve potential effects of FTY720 via modulation of 
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Baseline Intrarenal Artery Function Predicts Proteinuria in 
Obese Rats Prone to Develop Diabetes 
 
 













Zucker-diabetic-fatty rats (ZDF) are prone to develop diabetes-mellitus (DM) and 
nephropathy associated herewith. Here we studied the predictive-value of renal-artery 
function at pre-diabetic state in relation to future renal-damage during DM-development. 
Young-ZDF were subjected to unilateral-nephrectomy (UNx) (n=10), the endothelium-
dependent-relaxation (EDR) and myogenic-constriction (MC) determined in intrarenal-
arteries obtained from the individual's extirpated kidney and correlated with proteinuria-
increase 10-weeks thereafter as an indices of renal damage. Except for body-weight, 
metabolic parameters of young-ZDF were within normal range, indicating they were at the 
early onset of DM at the start of the study. UNx induced an initial steep-rise in proteinuria 
followed by a gradual-increase thereafter when ZDF developed signs of DM but with 
normotensive blood-pressure. The overall-proteinuria-increase following UNx and DM 
correlated with baseline EDR (r=-0.856, p=0.002) and MC (r=0.789, p=0.020). The 
findings demonstrate that baseline intrarenal-artery function predicted future renal-injury in 
obese subjects prone to develop DM. The smaller EDR predicting higher proteinuria-
increase suggests that reinforcement of endothelial function is a relevant target to prevent 
renal-damage in DM. In contrast, the larger MC predicting higher proteinuria-increase is 
opposite from findings in hypertensive models of renal-damage. This suggests for further 




































Despite displaying similar risk profiles, the development of chronic kidney disease (CKD) 
varies considerably among patients with conditions such as diabetes mellitus (DM), 
dyslipidemia and hypertension (HT) [1]. The high variability of development of renal 
damage between individuals also shows racial differences and genetic components [2-5]. 
Although the underlying mechanisms of this individual susceptibility to CKD are still 
largely unknown, a patent endothelial function as a powerful defense mechanism against 
organ injury has been implied [6,7]. Consistent with that we showed that baseline 
endothelial dilatory function of intrarenal arteries may predict an individual's susceptibility 
to CKD in a proof of principle study. In that study a smaller endothelium-dependent 
relaxation (EDR) measured at baseline in normal healthy rats predicted a higher degree of 
experimentally induced renal damage after 5/6 renal mass reduction [8]. However, whether 
baseline EDR also predicts CKD in natural or clinical courses of renal injury such as during 
DM development has not been studied previously.  
In addition to endothelial function and (local) neurohumoral mechanisms, myogenic 
responsiveness of small arteries also plays an important role in the organ’s microvascular 
function [9]. Intact myogenic constriction (MC) - i.e. the intrinsic ability of small vessels to 
constrict in response to increased intraluminal pressure - is believed to protect from 
exposure to large pressure and flow fluctuations and the potential damage hereof in end-
organs such as the eye, brain and kidney [9,10]. In Fawn-Hooded Hypertensive rats, loss of 
MC of small intrarenal arteries precedes hypertensive renal damage [11,12]. In normal rats, 
baseline MC predicted hypertensive renal damage after experimental 5/6 renal mass 
reduction [13]. However, whether baseline MC of intrarenal arteries may also have a 
predictive value for renal damage during DM development is unknown. 
It is hypothesized that the small intrarenal artery function plays an important role in the 
susceptibility and progression of renal injury in DM [9,14]. To study this we subjected 
young Zucker diabetic fatty rats (ZDF) rats to unilateral nephrectomy (UNx) when 7 weeks 
of age and still at the early onset of DM. Baseline renal artery function of the individual's 
extirpated kidney was assessed as EDR and MC and correlated with subsequent increases 
in proteinuria as an indices of renal damage development during 10 weeks thereafter. 
 
2. Materials and Methods 
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2.1. Animals and study design. The protocols for animal care and use were in accordance 
with the NIH Guide for the Care and Use of Laboratory Animals and approved by the 
Committee for Animal Experiments of the University of Groningen (Permit Number: 
DEC6032B). Studies were conducted using male obese ZDF (fa/fa) rats obtained from 
Charles River (France). Animals were housed group-wise in standard cages and maintained 
on a 12:12-hour light:dark cycle with free access to food (Purina LabDiet Formulab 5008) 
and normal tap drinking water throughout the study. After an one-week acclimatization 
period when animals were at 7 weeks of age, a blood sample was drawn from the tail vein 
and animals were put in metabolic cages for 24 hours for baseline measurements before 
they underwent UNx. For this, animals were anesthetized with 2.5% isoflurane in O2, the 
right kidney removed and the interlobular renal artery collected for vascular studies (ZDF-
UNx, n=10). Postoperatively, all animals received buprenorphin (Temgesic®; 0.01 mg/kg) 
subcutaneously for analgesic purposes. Animals were followed until 17 weeks of age and 
24h urinary protein excretion was assessed every 2 weeks. To control for the effect of UNx 
on the development of proteinuria in a setting DM development, another group of age-
matched ZDF rats was sham operated and concomitantly followed for proteinuria (ZDF-
sham, n=8). To further control for the effect of UNx per se on the development of 
proteinuria in the absence of DM, two additional groups of age-matched Zucker lean 
control rats (+/?) were either sham- or UNx-operated and concomitantly followed for 24h 
urinary protein excretion (lean-sham, n=8; lean-UNx, n=7). 
Ten weeks after surgery, ZDF-UNx rats were anesthetized (2.5% isoflurane in O2) and 
hemodynamic parameters measured by an invasive pressure transducer catheter (Micro-Tip 
3-French; Millar Instruments Inc., Houston, Tex., USA) inserted through the right carotid 
artery into the aortic root. After hemodynamic measurements, the ZDF-UNx animals were 
terminated by exsanguination and the kidney removed for analyses of glomerulosclerosis. 
2.2. Vascular measurements of baseline intrarenal artery function. Immediately after 
UNx, the nephrectomized kidney was weighed and transferred to the vascular laboratory. 
Small intrarenal arteries with an intraluminal diameter of 329±19µm were cleaned from 
perivascular tissue and used for measuring endothelial function and myogenic tone, as 
described previously [8,11,13]. For MC arteries were mounted in a perfusion pressurized 
setup (Living System Instrumentation, Burlington, VT, USA). In short, artery segments 
were cannulated on glass micropipettes in the vessel chamber that was filled and 
continuously recirculated with warmed (37°C) and oxygenated (5% CO2 in O2) Krebs 



























solution with a pH of 7.4. An inverted light microscope attached to a video camera and 
video dimension analyzer was used to evaluate the lumen diameter. Vessels were allowed 
to equilibrate for 30 min with 60 mmHg intraluminal pressure. Arteries were checked for 
smooth muscle viability and the endothelium denuded by means of a single high dose of 
phenylephrine (PE, 1 µmol/L). Subsequently, removal of the endothelium was confirmed 
by an absence of a response to methacholine (MCh; 20 µmol/L). Following a wash out, 
intraluminal pressure was equilibrated to 20 mmHg for 3 min. MC was assessed by a 
stepwise increase (20 mmHg) of the pressure up to 140 mmHg. Each pressure step was 
maintained for 3 minutes to reach a stable contraction. To obtain passive pressure curves 
the procedure was repeated but in the absence of calcium (calcium-free Krebs solution 
supplemented with ethyleneglycol-bis-(b-aminoethylether)-tetraacetic acid (EGTA, 2 
mmol/L). 
For assessment of endothelial function arteries were cut into 2-3 mm segments and 
mounted in a myograph setup (DMT model 610M, Denmark) filled with warm Krebs 
solution. As described previously [15], optimal wall tension was calculated as the vessel 
segment was stretched by stepwise increasing the distance between clamps in steps of 10 
µm until the transmural pressure exceeded 100 mmHg. The internal circumference and 
corresponding wall tension were fitted on an exponential curve for determination of L100 
(calculated diameter of the vessel at 100 mmHg). After calculation of the optimal wall 
tension, arteries were allowed to equilibrate for 30 minutes at 0.9 L100 before being pre-
constricted with 0.3 µmol/L PE. Pre-constricted vessels were studied for EDR by applying 
cumulative doses of MCh (1 nmol/L - 10 µmol/L). After addition of the last dose of MCh, a 
single high dose of sodium nitroprusside (SNP, 1 mmol/L) was given to test for maximal 
endothelium independent dilation. EDR and MC were successfully determined for 10/10 
and 8/10 ZDF-UNx rats, respectively. To confirm that baseline renal artery endothelial 
function and myogenic tone in young ZDF rats was within normal range, comparisons were 
made to 7 week old lean control rats. 
2.3. Clinical chemistry. Blood glucose and cholesterol were determined using Accu-Chek 
Aviva and AccuTrend (both Roche Diagnostics, Almere, Netherlands), and Hb1Ac using 
DCA Vantage (Siemens Healthcare Diagnostics Inc., Deerfield, IL) analyzers, respectively. 
Plasma and urine creatinine were measured by means of a photometric assay with the Jaffé 
method without deproteinization (DiaSys Diagnostics Systems, Holzheim, Germany). 
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Urinary protein excretion was measured in 24h urine collections by trichloroacetic acid 
precipitation (Nephelometer analyzer II; Dade Behring, Marburg, Germany). 
2.4. Renal histology. Coronal tissue slices through the mid portion of the kidney were fixed 
in 4% formaldehyde and embedded in paraffin, after which sections (4 μm) were stained 
with periodic acid-Schiff (PAS). Subsequently, glomeruli were semi-quantitatively scored 
for focal glomerulosclerosis (FGS) by light microscopy on a scale of 1 to 4, as described 
previously [16]. FGS was scored positive when mesangial expansion, mesangial cellularity, 
adhesion formation, and capillary obliteration was present in one segment. If 25% of 
glomerulus was affected, a score of 1 was adjudged, 50% was scored as 2, 75% as 3, and 
100% as 4. The ultimate score is then obtained by multiplying the degree of change by the 
percentage of glomeruli with the same degree of injury and adding these scores. A total of 
50 glomeruli per kidney were scored moving from cortex to medulla and the average value 
per kidney (i.e. per animal) calculated. The scoring was performed by two researchers in a 
blinded fashion. 
2.5.Solutions and drugs. The composition of Krebs solution was (in mmol/L): NaCl 
(120.4), KCl (5.9), CaCl2 (2.5), MgCl2 (1.2), NaH2PO4 (1.2), glucose (11.5), NaHCO3 
(25.0) at pH 7.4. Compounds for Krebs solution were obtained from Merck (Darmstadt, 
Germany) and all other drugs from Sigma-Aldrich (St. Louis, MO, USA).  
2.6. Calculations and data analysis. Data are presented as mean ± SEM; n values represent 
the number of investigated rats. IBM SPSS Statistics for Windows, Version 20.0 (Armonk, 
NY: IBM Corp.) was used for statistical analysis. In vascular studies, MC was expressed as 
percent decrease in active diameter from the maximally dilated (passive) diameter 
determined at the same pressure in calcium-free/EGTA solution, i.e., MC (%) = 100 [(DCa-
free – DCa)/DCa-free], where D is the diameter in calcium free (DCa-free) or calcium-containing 
(DCa) Krebs. EDR responses to MCh were expressed as a percentage of pre-constriction. 
Full pressure-myogenic response curves (in case of MC), concentration-relaxation curves 
(in case of EDR), and time-course curves (in case of proteinuria) were compared using 
repeated measures ANOVA. In addition to that the Area Under Curve (AUC, in arbitrary 
units) was determined for each individual MC and EDR curve and used for correlation and 
univariate linear regression analysis with parameters of renal damage. Unless stated 
otherwise, comparisons were performed using Student's paired or unpaired t-test, as 
appropriate; p<0.05 values were considered statistically significant. 
 




























3.1. Physical and biochemical parameters of obese ZDF rats. The data in Table 1 show 
that 17 week old ZDF rats had developed clear features of DM as blood values for plasma 
glucose, HbA1c, cholesterol and plasma creatinine (PCr) all were significantly increased 
compared to their respective values at 7 weeks of age. Renal parameters, such as urine 
production, creatinine clearance (CCr), protein excretion and FGS score, additionally 
demonstrated the development of renal damage once at 17 weeks of age. In contrast, at the 
start of the study when the animals were 7 weeks of age the metabolic parameters were 
within the normal range in ZDF and similar to that of age-matched lean control rats 
(8.3±0.4 mmol/L for glucose, 3.06±0.06 % for HbA1c, 2.01±0.17 mmol/L for cholesterol), 
except for increased body weight (269±5 and 205±5 g respectively, p<0.001). Other values 
for 7 week old ZDF and lean controls were: respectively 17.8±0.7 and 19.3±0.7 µmol/L for 
PCr, 6.097±0.250 and 5.640±0.235 mg/g for kidney-to-body weight, and 12.7±6.4 and 
6.6±0.6 mg/24h for urinary protein excretion (p=ns for all). The data confirm that at the 
moment UNx was performed the ZDF rats were obese and at the early onset of DM. 
Table 1.  Physical and biochemical parameters of obese ZDF rats. 
 ZDF rats (n=10) 
 Baseline  
(at 7 weeks of age) 
After UNx 
(at 17 weeks of age) 
Body weight (g) 269±5 477±17*** 
Right kidney weight (mg) 1629±76 - 
Left kidney weight (mg) - 3031±76 
Hemodynamic parameters   
Aortic HR (b.p.m.) - 278±6 
Aortic SBP (mmHg) - 118±4 
Aortic DBP (mmHg) - 72±2 
Blood parameters   
Glucose (mmol/L) 9.9±1.1 18.5±3.2* 
HbA1c (%) 3.56±0.08 5.88±0.57** 
Cholesterol (mmol/L) 2.95±0.19 5.40±0.58** 
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PCr (µmol/L) 17.8±0.7 32.3±0.8*** 
Renal parameters   
Urine production (ml/24h) 8.6±1.4 24.4±2.3*** 
CCr (ml/min/100g) 0.68±0.14 0.38±0.06** 
Protein excretion (mg/24h) 12.7±6.4 188.9 ±24.6*** 
FGS (%) - 50.3±5.9 
Abbreviations: UNx, unilateral nephrectomy; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; PCr, plasma creatinine; CCr, creatinine clearance; FGS, focal glomerulosclerosis. Data are mean ± SEM. 
*p<0.05, **p<0.01, ***p<0.001 (paired t-test). 
 
3.2. Inter-individual variation in baseline intrarenal artery function in young ZDF rats. 
Baseline EDR and MC was determined in intrarenal arteries obtained from the extirpated 
kidney at UNx. The mean concentration/pressure response curves for EDR and MC are 
presented in Figure 1A/B respectively, and demonstrate that at the group level small renal 
artery function in young obese ZDF was similar to that of age-matched lean controls. EDR 
and MC was also calculated as the Area Under Curve (AUC), presented for individual ZDF 
rats in Figure 1C. The data demonstrate normal EDR and MC in young obese ZDF with 
considerable inter-individual variation. 




























Figure 1. Baseline intrarenal artery function in young obese ZDF rats. Endothelium-dependent relaxation (EDR, 
panel A) and myogenic constriction (MC, panel B) in the group of young obese ZDF rats at the start of the study 
(open triangles) was not different from that in age-matched lean controls (closed circles); data are mean ± SEM. 
Panel C shows the variation in baseline EDR (n=10, left y-axis) and MC (n=8, right y-axis) of individual ZDF rats 
calculated as the area under the curve (AUC, arbitrary units); hence AUC was used in regression analysis of EDR 




3.3.Development of proteinuria in obese ZDF rats following UNx. In the follow-up period 
after the nephrectomy, ZDF rats developed progressive proteinuria (Figure 2A). 
Interestingly, development of proteinuria in ZDF-UNx rats seemed to consist of 2 phases; 
an early steep rise shortly after UNx (i.e. within 2 weeks) followed by a more gradual 
increase over time thereafter. To discriminate between the apparently two phases of 
proteinuria increase, we also calculated the change in proteinuria between weeks 0 and 2 
(early rise), weeks 2 to 10 (gradual rise) and the overall rise in proteinuria (weeks 0 to 10) 
(Figure 2B). The early steep rise in proteinuria was present in ZDF-UNx only. The gradual 
rise in proteinuria was present both in ZDF-UNx and ZDF-sham, albeit lower in the former, 
while the overall rise in proteinuria was highest in ZDF-UNx. Lean-sham and lean-UNx 
controls did not develop proteinuria. 




























Figure 2. Augmented increase in proteinuria in young obese ZDF following UNx. Starting at 7 weeks of age, 
24h urinary protein excretion was determined prior and after unilateral nephrectomy (UNx) or sham-surgery in 
Zucker diabetic fatty (ZDF) and age-matched lean control rats for 10 weeks. Panel A shows the actual time course 
of urinary protein excretion measured every 2-weeks for all groups. In addition to that the net-increase in urinary 
protein excretion was calculated from 0-to-2 (early), 2-10 (gradual), and 0-10 (overall) weeks after surgery, as 
shown in panel B. Hence, a marked early rise in proteinuria was present in ZDF-UNx rats only while the gradual 
increase was more similar between ZDF-sham and -UNx rats; consequently the overall increase in proteinuria was 
highest in ZDF-UNx rats. Data are mean ± SEM. ***p<0.001 ZDF-sham vs Lean-sham; ###p<0.001 ZDF-UNx vs 




3.4. Baseline intrarenal artery function predicting future proteinuria. To investigate 
whether intrarenal artery function in young ZDF rats predicted for future renal damage 
development, we plotted EDR and MC against the early-, gradual- and overall-rise in 
proteinuria in ZDF-UNx. Baseline EDR inversely correlated with the overall rise in 
proteinuria (Figure 3A). The inverse trend was also seen with the early- and gradual-rise in 
proteinuria but these did not reach statistical significance. MC positively correlated with the 
gradual- and overall-, but not the early-rise in proteinuria (Figure 3B). Hence, as 
measurement of EDR and MC of small renal arteries requires a nephrectomy, it was 
technically impossible to measure EDR and MC in the ZDF-sham and lean-sham groups. 
Further, lean-UNx do not develop proteinuria and were therefore also excluded from this 
analysis. 
 



























Figure 3. Baseline intrarenal artery function in young obese ZDF predicts future increase in proteinuria. 
Shown are scatterplots of renal artery endothelium-dependent relaxation (EDR, panel A) and myogenic 
constriction (MC, panel B) in young obese ZDF rats at the early onset of diabetes mellititus with increases in 
proteinuria following uninephrectomy (UNx). EDR and MC are presented as AUC (in arbitrary units). The early, 
gradual and overall increase in proteinuria was calculated as the difference from 0-2 (left panels), 2-10 (middle 
panels) and 0-10 (right panels) weeks after UNx at the start of the study. Fitted lines show the result of linear 
regression analysis with r- and p-values as indicated. 
 
3.5. Other baseline factors predicting future renal damage. In addition to EDR and MC, 
baseline HbA1c inversely correlated with MC (Figure 4A) and also showed a significance 
with the overall rise in proteinuria in univariate regression analysis (Table 2). Because of 
that we additionally performed a stepwise multivariate linear regression analysis with 
baseline EDR, MC and HbA1c being the factors included in the model (F-entry=0.05, F-
removal=0.10) to predict the overall rise in proteinuria. Two possible models were 
generated; model 1: r
2
=0.732 (p=0.007) with B=505.1±82.7 for constant (p<0.001) and B=-
2.8±0.7 for EDR with β=-0.856 (p=0.007), and model 2: r2=0.887 (p=0.047) with 
B=287.0±102.1 for constant (p=0.038), B=-2.0±0.6 for EDR with β=-0.608 (p=0.019) and 
B=0.08±0.03 for MC with β=0.465 (p=0.047). Hence, HbA1c did not reach significance as 
an independent predictor in either model. 
Finally we analyzed whether baseline parameters might predict for other indices of renal 
injury, including FGS, kidney weight and blood pressure (Table 2). A higher body weight 
at baseline was the only parameter significantly predicting a higher degree of FGS (Table 
2) and HbA1c was the only parameter measured significantly predicting a higher future 
kidney weight (Figure 4B). None of the baseline parameters significantly predicted blood 
pressure at the end of the study period. 
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Table 2. Linear regression analysis of baseline parameters and renal outcome parameters. 
 
Baseline parameters 
(assessed at the time 
of UNX) 





















        






































































































Abbreviations: UNx, unilateral nephrectomy; BW, body weight; EDR, endothelium-dependent relaxation; KW, 
kidney weight; MC, myogenic constriction; PCr, plasma creatinine; CCr, creatinine clearance; Prot. Excr., protein 
excretion; FGS, focal glomerulosclerosis; SBP, systolic blood pressure; ns, non-significant. BW is g, EDR is AUC 
in arbitrary units, MC is AUC in arbitrary units, HbA1c is %, cholesterol is mmol/L, PCr is µmol/L, CCr is 
ml/min/100g, Prot.Excr. is mg/24h; proteinuria is increase in Prot. Excr. from 0-2, 2-10 or 0-10 weeks after UNx, 



























FGS is %, SBP is mmHg, KW is mg/g body weight. Data represent r for univariate linear regression analysis with 
significant p-values in bold as indicated, or best non-significant correlation for a given outcome parameter in bold-
italic. 
 
Figure 4.  Scatterplots of baseline HbA1c with baseline intrarenal artery myogenic constriction (MC) and 
future kidney weight in young obese ZDF rats.  Baseline HbA1c positively correlated with intrarenal artery MC 
at baseline  (panel A) and predicted the relative kidney weight following uninephrectomy (UNx) and diabetes 




UNx in young obese ZDF at the early onset of DM induced an initial (UNx-driven) steep 
rise in proteinuria followed by a gradual (DM-driven) increase thereafter which was 
correlated with the variability in EDR and MC of intrarenal arteries at the start of the study. 
The present findings demonstrate that baseline intrarenal artery function predicted 
proteinuria as an indices of renal injury in obese subjects prone to develop DM.  
4.1. Augmented proteinuria increase following UNx in young ZDF rats; are obese 
subjects more susceptible to renal damage development? 
 In the ZDF rat model, development of DM induces renal injury and progressive proteinuria 
[17]. Here we additionally performed UNx to asses intrarenal artery function at the start of 
the study in young obese ZDF rats. Although UNx imposes increased filtration load to the 
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remnant kidney this normally does not lead to renal injury and development of proteinuria 
in otherwise healthy individuals due to renal reserve [18,19]. Consistent with that age-
matched lean control rats did not develop proteinuria when subjected to UNx. Hence, this 
renal reserve is also a crucial premise for living kidney donor transplantation. In young 
obese ZDF rats, however, UNx caused an early steep rise in proteinuria within 2 weeks. 
This while the normal range metabolic parameters in young ZDF rats indicate that they 
were (still) at the early onset of DM at the time of UNx. Since it was also lacking in lean-
UNx rats the results suggest that the steep rise in proteinuria following UNx was particular 
for obese subjects. 
To our knowledge the effects of UNx on proteinuria in ZDF rats have not been investigated 
previously. The closest may be a more recent study by Sebeková et al. [20] who assessed 
proteinuria in Zucker Fatty (ZF) rats at 8 weeks following UNx. Hence, ZF rats over time 
also develop features such as obesity, hyperglycemia and dyslipidemia, but not typically 
DM as in ZDF. In that study, proteinuria was ~26 mg/24h in ZF-UNx, compared to ~6 
mg/24h in lean-UNx [20], but this is still >7-fold lower than in ZDF-UNx and >4.5-fold 
lower than in ZDF-sham in the present study. Furthermore, UNx in the study by Sebeková 
et al. was induced in ZF rats at 4 weeks of age when body weight was (still) similar to that 
of age-matched lean controls [20]. So one important difference with respect to the present 
study seems to be the presence of obesity in young ZDF, augmenting the impact of UNx on 
susceptibility to renal injury as it seems. A second difference is the development of DM in 
ZDF, but not in ZF rats, accounting for the larger (gradual and overall) increase in 
proteinuria in ZDF compared to ZF. Interestingly, a higher body weight at baseline was 
correlated with a higher degree of future FGS (i.e. structural renal damage) in the present 
study. Taken together, the results suggest that obese subjects at the early onset of DM have 
augmented susceptibility for renal injury and development of proteinuria. This may 
generally adhere to the conclusion by Hernandez et al. [21] and others [22] that the 
metabolic syndrome - which includes obesity - should be considered an contraindication to 
donation because it is unclear how much risk there is for individuals who donate a kidney 
and then develop (renal) complications. Hence, according to the analysis of the American 
registry about 20% of the living donors presents obesity [23]. The tricky point obviously 
remains that - despite careful prescreening and close follow up care procedures - a uniform 
prediction or accountability of an individual's future development of obesity and/or other 
metabolic syndrome features remains uncertain. 



























4.2. Future development of proteinuria in young obese ZDF rats predicted by baseline 
intrarenal artery function; consistent predictive value of EDR but not of MC?  
To assess whether variation in intrarenal artery function would predict for the subsequent 
development of renal damage during DM we measured EDR and MC in small arteries 
obtained from extirpated kidney of young ZDF rats at the early onset of DM. EDR 
significantly predicted for the overall progression of proteinuria after UNx and 
development of DM in obese ZDF. Although EDR did not significantly predict for either 
the early-(i.e. UNx-driven) or the gradual-(i.e. DM-driven) rise in proteinuria, a trend 
towards a negative correlation between EDR and proteinuria was clearly observed here as 
well. Nevertheless, the results ultimately suggest that the predictive properties of EDR in 
young obese ZDF on overall proteinuria increase following UNx and DM development was 
dependent on the combination of the early rise plus gradual rise in proteinuria. Taken 
together, the present results further fuel the concept that an intact endothelial dilatory 
function generally provides a powerful defense mechanism against susceptibility for renal 
injury and progressive renal damage [6,14] and has a consistent predictive value including 
in DM. 
Next to EDR, intrarenal artery MC also predicted the overall increase of proteinuria in our 
model with similar correlation coefficients. Since we did not observe a correlation between 
MC and the early rise in proteinuria nor a trend thereto, we therefore conclude that the 
predictive properties of MC on the overall rise in proteinuria in our model was mainly 
mediated through the gradual component of proteinuria development, i,e. during the 
development of DM. Of importance, MC correlated positively with proteinuria in the 
present study which is in contrast to our previous findings [11,13]. But in those studies 
renal damage developed in the presence of HT. Hence, intact (or augmented) MC is 
believed to protect from an increase in intra-glomerular pressure in rats with elevated blood 
pressure [10,24]. Indeed, failure to maintain MC is associated with enhanced renal damage 
development in the hypertensive Fawn-Hooded rat, amongst others [11,12]. Vice versa, 
more pronounced MC of the pre-glomerular arteries is suggested to longer protect the 
kidneys from HT-damage in spontaneous hypertensive rats (SHR) [24]. However, as obese 
ZDF do not develop HT – at least not within the study period in the present study - the role 
of renal artery MC in non-HT models of renal injury seems less clear. 
4.3. Other baseline parameters predicting future renal damage in obese ZDF rats 
developing DM.  
Chapter 2 
 40 
Apart from intrarenal artery EDR and MC, baseline HbA1c was the only additional 
parameter predicting future proteinuria. Similar to EDR and MC, baseline HbA1c varied 
among individuals but was still within the normal range at the start of our study. 
Interestingly, baseline HbA1c also positively correlated with baseline MC (Figure 4A). At 
present, the mechanism behind a possible interaction between MC and HbA1c is unknown. 
Previously, it has been shown that augmented oxidative stress and enhanced intrarenal 
angiotensinogen precede the development of renal injury in the ZDF rat [25]. Additional 
reports suggest that reactive oxygen species generated from nox2-based NADPH oxidase 
may augment intrarenal artery MC in SHR, and also AT1-receptor activity has been linked 
to increased MC reactivity [26,27]. Furthermore, obesity per se is associated with oxidative 
stress and also glucose levels – as reflected by HbA1c [28] – play a role in determining 
oxidative status [29]. The variations in baseline MC in association with baseline HbA1c in 
the present study may thus have reflected inter-individual variation in oxidative status at the 
early onset of DM in young obese ZDF.   
Higher basal HbA1c levels also predicted for increased kidney-to-body weight ratio as an 
indices of renal injury. Increased kidney weights has been reported previously in ZDF at 16 
weeks of age [30]. Clinical studies have demonstrated that the combination of HbA1c and 
fasting glucose predict for the development of DM. Results of the present study suggest 
that the predictive value of basal, normal-range HbA1c may even be extended to the 
progression of renal injury after development of DM. 
 
Conclusions, limitations and perspectives 
Proteinuria increase following UNx was augmented in young obese ZDF rats at the early 
onset of DM. Although this in itself was a secondary finding it does refer to previous 
suggestions [31] that obesity in otherwise healthy subjects may increase susceptibility to 
renal damage. In contrast, blood pressure was not increased following UNx. It should be 
acknowledged, however, that hemodynamic parameters were obtained under anesthesia 
which might have limited the detection of potential mild increases in blood pressure to 
some extent. 
Previous proof of principle studies indicated that baseline variation in intrarenal artery 
function could have a predictive value for an individual's susceptibility to renal injury and 
CKD [8,11,13,14]. However, the findings of those studies are limited by the fact that renal 
injury and CKD was induced experimentally rather than the result of natural or clinical 



























courses such as in DM. As a primary objective, we here found that smaller EDR in young 
ZDF rats - in which development of DM is accompanied by functional and morphological 
kidney damage [17] - independently predicted increased future proteinuria. It thereby 
adheres to the concept that an intact endothelial dilatory function generally provides a 
powerful defense mechanism against susceptibility for end-organ damage, including renal 
injury and progressive renal damage in DM. Given the consistency with which intrarenal 
artery EDR predicted proteinuria, future studies may designed to test whether early 
modulations aimed at the reinforcement of “normal” endothelial function also attenuate an 
individual’s susceptibility to renal damage in obese subjects prone to develop DM. 
Baseline variation in intrarenal artery MC also predicted future proteinuria in the present 
study but its direction (i.e. a larger MC predicted for more proteinuria during DM) was 
opposite from that observed previously. Thus in contrast to EDR, the predictive value of 
intrarenal artery MC for renal injury seems less consistent which suggests for further 
investigations hereof. It should additionally be noted here that - given the alleged protective 
role of intact MC against glomerular damage from barotrauma - such future studies should 
have a particular notion regarding the absence (i.e. as in the present study) or presence (i.e. 
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Diabetes and particularly high blood glucose levels are implicated in neurodegeneration. 
One of the hallmarks of neurodegeneration is protein aggregation. We investigated the 
presence of protein aggregation in the frontal brain of Zucker diabetic fatty (ZDF) rats, an 
animal model for diabetes. Further, the effect of NaHS in suppressing protein aggregation 
in cultured brain slices from ZDF was assessed. The levels of protein synthesis, 
protein/gene expression, autophagy and anti-oxidant defense were evaluated in ZDF and 
control (Lean) brains. Compared to Lean, ZDF brains displayed a significant increase in 
protein aggregates, p-tau, fibronectin expression and protein glycosylation. Increased 
phosphorylation of mTOR and S6 ribosomal protein in ZDF indicated higher protein 
synthesis, while the increase in ubiquitinated proteins and LC3-I in ZDF brains 
accompanied by lower LC3-II expression and LC3-II/LC3-I levels indicated the blockage 
of proteolytic pathways. CBS (cystathionine beta synthase) protein and mRNA expression 
and thiol group levels in ZDF brains were lower compared to Lean. ZDF brains show a 
higher level of reactive oxygen species. In vitro NaHS treatment normalized proteostasis 
while counteracting oxidative stress. Our data demonstrate increased protein synthesis and 
aggregation in the diabetic ZDF rat brain, which was reversible by NaHS treatment. This is 
the first report on the potential use of NaHS as a novel strategy against protein aggregation 







































Impairment of cognitive function is a feature that has been observed in diabetes, especially 
in type II diabetic patients [1,2], although the relationship remains disputed. Increased 
glycated hemoglobin 1 (HbA1c), indicating increased average blood glucose levels over a 
longer period, is related to lower cognitive function in individuals with type 2 diabetes and 
the decline in glycemic control is related to lower scores on cognitive function tests [3]. In 
turn, this is in accordance with the finding of advanced glycation end-products (AGEs) in 
dementia and diabetic microvascular disease, in which decreased cerebral glucose 
metabolism is observed [4]. Indeed, low rates of glucose metabolism in brain cells lead to 
the accumulation of glycoproteins associated with subsequent formation of cytotoxic 
aggregates in brain [5]. Animal experiments also suggest a relationship between diabetes 
and cognitive impairment, as observed in type 2 diabetic models of genetically obese 
Zucker rat or db/db mouse [6] and in type 1 diabetic models of streptozotocin-induced 
diabetes mellitus in rat [7] and mouse [8]. As neurodegenerative diseases are often 
characterized by defects in brain protein maintenance [9], we employed an inbred model for 
type 2 diabetes the fa/fa Zucker diabetic fatty (ZDF) rat to study the effects of high glucose 
concentration on protein expression in brain. Moreover, there is still a lack of strategies to 
inhibit diabetes induced toxic protein aggregate formation in tissues which could be to 
some degree answered by our research. 
Protein aggregate formation affects cellular function and has been implicated in various 
aging related disorders [10] and complications [11]. Protein aggregation is a common 
feature of neurodegenerative diseases leading to neurofibrillary tangle formation with 
cognitive deficits [12], including Alzheimer’s, Parkinson’s and Huntington’s disease, 
amyotrophic lateral sclerosis, frontotemporal dementia, ataxias, and human prion diseases. 
In many neurodegenerative complications such as Alzheimer’s, these tangles contain PHF 
(paired helical filaments) which are highly insoluble structures, composed of a highly 
phosphorylated form of the microtubule-associated protein tau. Although the 
characterization of brain protein aggregation is still insufficiently reported in type 2 
diabetes, the close similarity in protein aggregate formation between Diabetes and 
Alzheimer’s may indeed indicate that the two conditions share key mechanistic targets [13]. 
It has been suggested that mTOR (mammalian target of rapamycin), which is an established 
component in proteostasis known to be implicated in different neurodegenerative 
complications [14], may represent an important link between nutrient excess with obesity 
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and insulin resistance and their possible complications [15]. Although mTOR is an 
important regulator of neuronal development and function, including tau expression [16], to 
date only few studies have addressed a possible implication of mTOR in diabetes in relation 
to protein aggregate formation in brain tissue. Considering the induction of mTOR by high 
glucose levels [17], the mTOR pathway is likely implicated in the induction of brain 
protein aggregation in diabetes [18]. The presence of oxidative stress due to reactive 
oxygen species (ROS), and increased protein glycosylation leading to protein-protein 
crosslinking or aggregation [19] might be additional factors involved. 
Different mechanisms deal with misfolded proteins to prevent the accumulation of 
aggregates. One such mechanism is autophagy, which removes ubiquitinated misfolded 
protein aggregates. In the light of possible mTOR activation (see above) [20], autophagy 
may be inhibited by phosphorylation of ribosomal protein S6, a main downstream effector 
of mTOR [21]. In addition, degradation by the ubiquitin-proteasome system seems 
involved in the clearance of misfolded proteins, especially oxidative stress induced 
ubiquitinated (UB) proteins that are resistant to breakdown via autophagy and ubiquitin 
routes [22]. Although acute oxidative stress induces autophagy [23], it is still conceivable 
that in diabetes the chronically increased levels of glucose may lead to imbalances in the 
antioxidant capacity within the cell. In turn, this would result in oxidative stress-mediated 
injury [24] which may impair autophagic clearance routes as observed in cells cultured at 
high glucose concentrations [25], thus further contributing to the formation of highly 
insoluble aggregates. 
Another defense mechanism against protein aggregate formation constitutes of brain 
antioxidants such as FABP, thiol groups or H2S which would restrict oxidative damage by 
high glucose concentrations. It is known that pyridoxamine, an antioxidant and allosteric 
activator of the H2S producing enzyme cystathionine beta synthase (CBS) inhibits AGE 
formation [26] and protects cells from oxidative damage [27]. We have previously shown 
that H2S, as NaHS, modulates mTOR pathway in aging Werner syndrome skin fibroblasts 
and inhibits protein aggregation and aging phenotype while diminishing oxidative stress 
[28]. Further H2S has been also shown to induce protective autophagy in colon epithelial 
cells [29]. Nevertheless, the effect of H2S on inhibition or reversal of protein aggregation 
has yet not been studied in diabetic brain. 
The first aim of this study was to identify diabetes induced protein aggregation in brain 
tissue obtained from an animal model of diabetes mellitus type 2. As frontal brain is 
























implicated in cognitive behavior [30], we established the nature of protein aggregates in 
this brain region in 17 weeks old Zucker diabetic fatty rats (ZDF) compared to age matched 
Lean controls, and explored proteostasis routes. As we found changes in brain proteostasis 
to coincide with lower levels of brain thiol groups and diminished expression of CBS in 
ZDF, we sought as a second aim to investigate a potential beneficial effect of H2S. 
However, others have previously demonstrated that administration of H2S (as NaHS) 
influences glycemic control in vivo thus changing blood glucose and HbA1c levels [31,32]. 
Therefore, we examined the effect of NaHS treatment on proteostasis in cultured brain 
tissue slices to assess the direct effects of H2S on brain, while excluding confounding 
effects of the modulation of glycemic control. 
 
Results 
HbA1c and glucose concentrations 
Development of diabetes in ZDF was monitored by measurement of HbA1c, glucose and 
body weight (Table 1). Body weight of ZDF animals was significantly increased compared 
to age matched Lean controls at all-time points examined. Moreover, the increase in body 
weight of ZDF animals between week 7 and 17 (100 ± 4% (p < 0.05)) was 27% higher 
compared to the increase observed in Lean animals between week 7 and 17 (73 ± 2% 
(p < 0.05)). The impairment of glycemic control in ZDF animals was evidenced by both 
significantly higher blood glucose and HbA1c levels compared to Lean at all-time points 
examined. At week 17 in ZDF the percent difference to Lean amounted to 25 ±0.5% and 30 
±0.4% (p < 0.05) for blood glucose and HbA1c respectively. The increase in blood glucose 
of ZDF animals between week 7 and 17 (19 ± 2% (p < 0.05)) was 13% higher compared to 
the increase observed in Lean animals between week 7 and 17 (6 ± 0.5% (p < 0.05)). In 
addition, the increase in HbA1c level of ZDF animals between week 7 and 17 (50 ± 2% 
(p < 0.05)) was 33% higher compared to the increase observed in Lean animals between 
week 7 and 17 (17 ± 3% (p < 0.05)). Finally, the glucose concentration in the brain 
homogenates of the ZDF group (2.9 ± 0.7 mmol/kg) was found to be significantly higher 
than in the Lean group (1.3 ± 0.1 mmol/kg, p < 0.05). Together, these data demonstrate 
significantly impaired glycemic control in ZDF, yet without the full blown development of 




Table 1. Development of diabetes in ZDF (zucker fatty rat) was monitored by measurement of HbA1c, glucose 
and body weight. ZDF rats show clear signs of diabetes as from week 7 onwards, as all 3 components show a 
significant increase compared to lean animals. 
 wk 7 Wk 9 Wk 11 wk13 wk 15 wk 17 
Glucose (mmol/l)       
Lean 7.8±0.4 8.9±0.1 8.3±0.2 8.3±0.2 8.5±0.3 8.3±0.2 
ZDF 11.2±1.4* 9.9±0.6* 9.2±0.4* 9.6±0.4* 10.6±1.0* 11.0±1.0* 
       
HbA1c (%)       
Lean 2.9±0.01    3.4±0.02 3.4±0.05 
ZDF 3.3±0.04*    4.8±0.13* 5.0±0.24* 
       
Body weight (g)       
Lean 211±5 247±4 280±3 317±5 341±6 365±5 
ZDF 252±7* 332±9* 395±7* 449±5* 486±7* 504±9* 
Data are mean ± SEM. *p<0.05 Lean vs. ZDF  
 
Protein aggregates, tau and fibronectin expression 
The silver stain showed a doubling of the number of protein aggregates present throughout 
the frontal brain in ZDF (Figure 1A). The aggregates were seen as black/brown entities 
with a tangled conformation (Figure 1C). To further substantiate increased protein synthesis 
in ZDF brains, the ratio of protein-to-DNA was measured. This ratio was significantly 
increased in ZDF brains showing higher protein synthesis levels in ZDF brains (Figure 1B). 
The expression of tau and fibronectin were investigated by Western blot analysis and qPCR 
analysis. Tau protein levels were increased in ZDF brains compared to Lean (Figure 1D). 
Especially tau protein isoforms with molecular weights around 55 and 65 kDa [33] were 
increased in frontal sections of ZDF compared to Lean (Figure 1D). In 
immunohistochemistry analysis, tau protein was seen as black/brown entities with an intact 
pattern in Lean brain but a dispersed pattern in ZDF brain (Figure 1F), which may suggest 
the cleavage of tau protein in ZDF. Total tau mRNA levels also showed a two times 
increase in ZDF brains (Figure 1E). Fibronectin protein expression was investigated 
because of its higher level of expression in diabetes [34] and also its presence in 
neurodegenerative diseases [35]. We observed that fibronectin protein in frontal brain of 
ZDF was about 3 times higher compared to Lean (Figure 1G). This was also confirmed by 
























immunohistochemistry analysis of brain tissue (Figure 1I). Fibronectin mRNA levels were 




Figure 1. Excess protein aggregation in the frontal brain of ZDF (zucker diabetic fatty rat) compared to 
Lean. (A) ZDF brain shows doubling of the expression of protein aggregates (tangles). (B) Higher protein 
synthesis levels in ZDF brains indicated by higher protein/DNA ratio. (C) ZDF brain shows increased number of 
neurofibrillary tangles. Silver staining depicts tangles in dark brown/black elements with a diameter of 10–20 μm 
as magnified in top inset. (D) ZDF displays increased levels of tau proteins as found by Western 
blotting. (E) Real-time PCR analysis of the mRNA expression of total tau relative to β-actin. (F) ZDF displays 
increased levels of tau protein isomers and tau protein cleavage as found by immunohistochemistry (indicated by 
→). (G) ZDF displays increased levels of fibronectin as found by Western blotting. (H) Real-time PCR analysis of 
the mRNA expression of fibronectin relative to β-actin. (I) Immunohistochemistry analysis shows higher 
fibronectin expression in ZDF rats in comparison with Lean (indicated by →). Magnification 40×, Data are 
Means ± SEM (n ≥ 5 per group), * <0.0001 (difference to control gray bars in each group); unpaired t-test. Western 
blot expression is normalized to β-actin; lanes of western blot insets are in the same order as in the X-axis. 
 
Proteostasis components 
Increased expression of proteins such as tau and fibronectin in the face of aggregate 
formation may denote derailment of proteostasis in neurons. Therefore, we examined 
activation of the mTOR pathway as a major route controlling protein synthesis, as well as 
protein degradation by autophagy and ubiquitylation. ZDF brain demonstrated an increased 
expression of mTOR and phosphorylation of mTOR (p-mTOR serine 2448) in ZDF (Figure 
2A). Next, we examined ribosomal protein S6 (S6), being the immediate downstream target 
of the mTORC1 pathway conveying increased protein synthesis. In brain of ZDF, 
expression of both S6 and phosphorylated S6 (p-S6) was markedly elevated compared to 
Lean (Figure 2B). The ratios of the phosphorylated forms of mTOR and S6 ribosomal 
protein over the total expression of these proteins in brain was increased for both mTOR 
(Figure 2C) and S6 (Figure 2D) in ZDF brains, disclosing the activation of the mTOR 
pathway. To examine autophagy, Western blotting for LC3 (Microtubule-associated protein 
1 light chain 3) was performed. ZDF rats showed an increased expression of LC3-I, with 
lower expression of LC3-II compared to Lean (Figure 2E). The ratio of LC3-II-to-LC3-I in 
ZDF brains is halved compared to Lean brain showing lower autophagy levels in ZDF 
brains (Figure 2F). Also, ZDF brains showed increased levels of mono- and 
polyubiquitinated proteins (Figure 2G). Collectively, these data substantiate the impairment 
of proteostasis in ZDF brain consisting of increased protein synthesis and degradation via 
the proteosomal route accompanied by lower autophagy levels. 

























Figure 2. mTOR pathway activity, autophagy and protein ubiquitination in brain of ZDF (zucker diabetic 
fatty rat). (A) Increased expression of mTOR and its phosphorylated form in ZDF detected by an antibody raised 
against phosphorylation on serine 2448. (B) Increased S6 ribosomal protein (S6) and its phosphorylated form (p-
S6) in ZDF. (C) Increased mTOR activity in ZDF. (D) Increased S6 protein activity in ZDF. (E)Increased 
expression of LC3-I and the decrease in LC3-II levels in ZDF. (F) Autophagy levels are lower in ZDF compared 
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to Lean as shown by LC3-II/LC3-I ratio. (G) Increased levels of mono- and polyubiquitinated proteins in ZDF. 
Insets: typical examples of Western blot data showing protein of interest (upper part) and β-actin (lower part). 
Data are Means ± SEM (n ≥ 5 per group), * <0.0001 (difference to control gray bars in each group); unpaired t-test. 
Western blot expression is normalized to β-actin; lanes of western blot insets are in the same order as in the X-
axis. 
 
Glycosylation and reactive oxygen species damage 
Diabetes is associated with increased ROS (Reactive oxygen species) production, part of 
which is explained by glycosylated protein species inhibiting the electron transport chain of 
mitochondria [36]. Indeed, ZDF brain showed a slight, but significantly increased level of 
carboxymethyllysine (CML), indicating the presence of glycosylated protein species 
(Figure 3A). Moreover, HIF1A (Hypoxia inducible factor 1) levels, known to be 
upregulated through ROS formation [37], were increased in ZDF brains (Figure 3B). Also, 
ZDF brain showed a lower expression of FABP (Figure 3C), a protein depleted by ROS 
damage. Further, a fluorogenic probe was used to assess the formation of ROS in brain 
tissue. ROS formation in brain homogenate was doubled in ZDF compared to Lean (Figure 
3D). 
 
Figure 3. Oxidative stress and damage in brains of ZDF rats. (A) Expression of CML/AGE is increased in 
ZDF compared to Lean. (B) HIF1A expression is higher in ZDF brain compared to Lean. (C) FABP is 3 times 
























lower in ZDF rats compared to Lean. (D) ROS formation is higher in ZDF brains compared to Lean. ROS 
formation is measured by the level of Fluorescin fluorescence. Western blot data showing protein of interest 
(upper part) and β-actin (lower part). Data are Means ± SEM (n ≥ 5 per group), * <0.0001 (difference to control 
gray bars), unpaired t-test. Western blot expression is normalized to β-actin; lanes of western blot insets are in the 
same order as in the X-axis. 
 
Brain CBS expression and thiol group content 
Expression of CBS (H2S producing enzyme) and brain thiol groups were assessed in brain 
to evaluate the antioxidant defense levels. CBS protein expression (Figure 4A), CBS 
mRNA levels (Figure 4B) and % thiol groups (Figure 4C) were found to be significantly 
lower in ZDF brain compared to Lean. 
 
Figure 4. Thiol groups and CBS (cystathionine beta synthase) expression in ZDF (zucker fatty diabetic rat) 
and Lean frontal brain. (A) CBS expression is lower in ZDF brains. (B) Real-time PCR analysis of the 
expression of CBS relative to β-actin, and (C) Thiol group level in ZDF is lower than Lean. Western blot data 
showing protein of interest (upper part) and β-actin (lower part). Data are Means ± SEM (n ≥ 5 per group), * 
<0.0001 (difference to control gray bars), magnification 40×; unpaired t-test. Western blot expression is 
normalized to β-actin; lanes of western blot insets are in the same order as in the X-axis. 
 
NaHS treatment diminishes protein aggregation 
To examine the pharmacological potential of H2S in counteracting the defective 
proteostasis in ZDF brains while excluding the beneficial effects of H2S in lowering 
glucose concentrations in the whole animal [31], H2S was administered to cultured brain 
slices. To this end we used culture medium with 35 mM of glucose, as initial experiments 
had shown that the normal medium (25 mM glucose) diminishes protein aggregation in 
brain (data not shown). To this end, slices of ZDF brain were treated with 50 μM NaHS 
every 10 h for two days. Brain slice viability and apoptosis was substantiated by MTS and 
caspase 3/7 assays (Figure 5). Cultured brain slices retained protein aggregates (Figure 6A). 
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The number of aggregates was doubled in ZDF brain slices compared to Lean. Treatment of 
ZDF brain slices with NaHS, however, reduced the number of aggregates to Lean levels 
(Figure 6B). N-acetyl cysteine (NAC) lowered the number of aggregates but to a lower 
degree compared to NaHS (Figure 6A-B). Further, protein synthesis level was substantiated 
by calculating the ratio of protein-to-DNA. This ratio was increased in ZDF brain slices 
showing higher protein synthesis levels in ZDF, while NaHS counteracted this increase 
showing inhibitory properties on protein synthesis (Figure 6C). A similar pattern of 
decrease through NaHS treatment was also found for the other markers. The 65 kDa tau 
species expression was 3-fold higher in ZDF slices compared to Lean and NaHS treatment 
was found to normalize tau expression in ZDF brain (Figure 6D). Further, 
hyperphosphorylated tau, as detected by the AT8 antibody, was present at 70 kDa in ZDF 
brains which was decreased by NaHS treatment (Figure 6D). Also, fibronectin expression 
was doubled in ZDF compared to Lean and was normalized by NaHS treatment (Figure 
6E). 
Figure 5. Tissue viability (MTS assay) and apoptosis (caspase 3/7 activity) in cultured brain slices. Left 
panel: Cells dissociated from two days NaHS treated ZDF slices show the highest level of viability with the lowest 
levels of apoptosis compared to cells in slices from Lean and ZDF or the fully viable non-cultured slices which 
show 100% viability. Right panel: Cells dissociated from the untreated ZDF slices show the highest caspase 
activity in culture, which is decreased below the level of Lean by treatment with NaHS. Data are means ± SEM 
(n ≥ 5 per group), * = different from control gray bars, * < 0.05; One way ANOVA. 

























Figure 6. Treatment with NaHS counteracts protein aggregates in cultured brain slices from ZDF (zucker 
diabetic fatty rat). (A) ZDF brain slices retain protein aggregates in culture. Protein aggregates are diminished 
through NaHS treatment. NAC diminishes protein aggregates in ZDF. (B) The doubling of the number of 
aggregates in ZDF brain slices is lowered to Lean levels by NaHS treatment. NAC lowers protein aggregates in 
ZDF brain but at a much slower rate. (C) NaHS lowers the higher protein synthesis levels in cultured ZDF brains 
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indicated by higher protein/DNA ratio. (D)65 kDa and 55 kDa tau expression is three times higher in ZDF rats 
compared to Lean and NaHS treatment normalizes tau levels. Also, hyperphosphorylated tau (AT8) is increased in 
ZDF brains and normalized by NaHS. (E) Fibronectin expression is doubled in ZDF rats compared to Lean and is 
normalized by NaHS treatment. (F) Real-time PCR analysis of the expression of total tau relative to β-actin. NaHS 
lowers total tau expression in ZDF to lower than Lean levels (G) Real-time PCR analysis of the expression of 
fibronectin relative to β-actin. NaHS lowers fibronectin expression in ZDF to lower than Lean levels. Western blot 
data showing protein of interest (upper part) and β-actin (lower part) from the same samples. Data are 
means ± SEM (n ≥ 5 per group) *, #, + <0.05 = statistically different, * different from control gray bars in each 
group, # different from ZDF group, + different from lean, ZDF and ZDF + H2S; One way ANOVA. Western blot 
expression is normalized to β-actin; lanes of western blot insets are in the same order as in the X-axis. 
 
The levels of total tau mRNA (Figure 6F) and fibronectin mRNA (Figure 6G) was higher in 
ZDF brains compared to Lean and this increase in mRNA levels was counteracted and 
lowered to below mRNA levels present in Lean brains. 
The phosphorylation of mTOR and S6 ribosomal protein was 4 times higher in cultured 
brain slices from ZDF and both were lowered to normal levels by NaHS treatment (Figure 
7A,B). Also the total levels of mTOR (Figure 7A) and S6 ribosomal protein (Figure 7B) 
were higher in ZDF and were lowered to below the expression observed in Lean brains by 
NaHS treatment. The ratios of the phosphorylated forms of mTOR and S6 ribosomal 
protein to the total expression of these proteins in each sample show activation of mTOR 
(Figure 7C) and S6 ribosomal protein (Figure 7D) in ZDF brains which is fully 
counteracted by NaHS treatment. LC3-I expression was 2 times higher in ZDF rat brain 
slices and its level was decreased through NaHS treatment (Figure 7E). The ratio of LC3-II-
to-LC3-I in ZDF brains was two times lower compared to Lean brains showing lower 
autophagy levels in ZDF brains. NaHS strongly increased autophagy levels in ZDF brains 
(Figure 7F). Mono- and polyubiquinated protein expression was 3 times higher in ZDF 
brains and was also lowered to Lean levels by NaHS treatment (Figure 7G). 

























Figure 7. Treatment with NaHS modulates protein synthesis and degradation pathways in cultured brain 
slices from ZDF (zucker diabetic fatty rat). (A) The expression of mTOR and its phosphorylated form (p-
mTOR2448) is higher in ZDF and is lowered to normal levels by H2S treatment.(B) The expression of S6 protein 
and its phosphorylated form (p-S6 ribosomal protein) is higher in ZDF rats and is normalized by NaHS 
treatment.(C) Increased mTOR activity in ZDF is counteracted by NaHS. (D) Increased S6 protein activity in ZDF 
is counteracted by NaHS. (E) LC3-I is higher in ZDF brains while LC3-II shows lower expression. NaHS lowers 
LC3-I expression. (F) Autophagy levels are lower in cultured ZDF slices compared to Lean as shown by LC3-
II/LC3-I ratio. NaHS increases autophagy levels in ZDF. (G) Mono- and polyubiquitinated protein expression is 3 
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times higher in ZDF brains compared to Lean and is lowered to normal by NaHS. Western blot data showing 
protein of interest (upper part) and β-actin (lower part) from the same samples. Data are means ± SEM (n ≥ 5 per 
group), * < 0.05 = different from control gray bars in each group; One way ANOVA. Western blot expression is 
normalized to β-actin; lanes of western blot insets are in the same order as in the X-axis. 
 
HIF1A expression was not found different between ZDF and Lean brains in vitro, but 
NaHS increased the expression of this protein in ZDF (Figure 8A). FABP expression was 
reduced in ZDF brain slices compared to Lean. NaHS treatment of ZDF brains did not 
affect FABP expression (Figure 8B). The assessment of ROS levels shows that treatment of 
Lean at high glucose concentrations did not change ROS levels. ROS production in ZDF 
brains was inhibited by the addition of NaHS or NAC (Figure 8C). 
 
Figure 8. NaHS counteracts oxidative stress and damage in brain slices of ZDF rats. (A) HIF1A expression is 
similar in ZDF and Lean brains but NaHS increases the expression of this protein. (B) FABP expression is 
decreased in ZDF and is unaffected by NaHS treatment. (C) ROS production is twice higher in ZDF brains 
























compared to Lean. NaHS an NAC (N-acetyl-L-cysteine) inhibit ROS formation in ZDF slices. ROS formation is 
measured by the level of Fluorescin fluorescence. (D) The oxidized forms of Peroxiredoxins is twice higher in 
ZDF brain and is reversed to non-oxidized form through NaHS and NAC treatment. Western blot data showing 
protein of interest (upper part) and β-actin (lower part) from the same samples. Data are means ± SEM (n ≥ 5 per 
group), * < 0.05 = different from control gray bars; One way ANOVA. Western blot expression is normalized to β-
actin; lanes of western blot insets are in the same order as in the X-axis. 
 
Peroxiredoxin (Prx) enzyme modulates oxidative stress via its evolutionary conserved 
cystein (Cys) residues. Under oxidative stress condition, cystein sufinic acid of Prx 
becomes oxidized. To further study the potential oxidation of Prx enzymes under oxidative 
stress in ZDF brain, we performed Western blot analysis with oxidized Prx specific 
antibody, anti-Prx-SO3 in all samples. Our results show that Peroxiredoxins is highly 
oxidized in ZDF brain and that NaHS and NAC reverse this process (Figure 8D). 
Thus, NaHS might be counteracting the defective proteostasis and protein aggregation in 
cultured ZDF brain slices through reduction in protein synthesis and inhibition of oxidative 
stress. 
 
Discussion and conclusion 
Our data demonstrate the increase in protein aggregates in brain of ZDF rats probably due 
to a derailment in protein homeostasis, which was reversed in vitro by treatment with 
NaHS. It appears that several factors might be contributing to protein aggregation in ZDF 
brains. First, protein synthesis is enhanced, as evidenced by the increase in the expression 
and activation of mTOR and S6 proteins in ZDF brains. Further, the loss of proper defense 
against the increased oxidative stress seems to be involved, as demonstrated by decreased 
levels of FABP, thiol levels and CBS and higher amounts of glycosylated proteins in ZDF. 
Finally, the clearance mechanisms for deviant proteins seem impaired, as demonstrated by 
the excess of ubiquitinated proteins (UB-proteins) and a relative impairment of autophagy 
in ZDF. The exact order and contribution of these factors in ZDF is hard to unravel. Yet our 
experiments in brain slices cultured under increased glucose conditions suggest that the loss 
of oxidant defense has an important role, as aggregates from ZDF were abolished by 
treatment with NaHS, which is known to be a strong cytoprotective antioxidant [27,38]. In 
addition, we also found NaHS to inhibit the mTOR pathway and the resulting inhibition of 
protein synthesis is likely contributing to the beneficial effects of NaHS on protein 
aggregation. Together, our results suggest that diabetes induces protein aggregation in brain 
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of ZDF rats and could potentially provide a basis for possible therapeutic strategies in 
cognitive disorders related to protein aggregation. 
Our data disclose the presence of protein aggregates in ZDF brains. Tau and its 
hyperphosphorylated form (recognized by AT8 antibody) is one of the main neuronal 
proteins involved in protein aggregation [39] and has been implicated in the loss of 
cognitive performance [39]. Hyperphosphorylated tau (p-tau) has been observed previously 
in the brain of mice models of type 1 and 2 diabetes [40]. Importantly both p-tau [41] and 
protein aggregates have been found in the brain of streptozotocin (STZ) induced mouse 
model of type 1 diabetes [42]. Thus, the increased total tau mRNA together with 
phosphorylation of tau protein in ZDF rat brains, might cause impairment in cellular 
function and cognitive disorders [43]. Tau hyperphosphorylation in diabetes might be due 
the tau protein cleavage inducing toxic tau aggregation. Indeed, we observed a dispersed 
pattern of tau protein staining, which might suggest the cleavage of tau protein in ZDF 
brain, consistent with a recent report suggesting that tau cleavage is an early event in 
aggregate pathology [44]. Possibly, high glucose is implicated in ROS formation [45] and 
the increase in tau cleavage and phosphorylation might be secondary to the chronic 
presence of ROS in diabetes [46]. The increase in advanced glycation end-products (AGEs) 
due to protein glycation in ZDF, as exemplified by the increased CML expression, may 
constitute a core for protein aggregation and probably underlie the process of cognitive 
decline [47]. High glucose is implicated in the increase in CML in ZDF brains [48] and the 
increase in fibronectin, a component of extracellular matrix, we observed, may also be due 
to higher glucose levels and the subsequent excessive ROS formation, as found previously 
in astrocytes [49]. 
Our data implicate that several changes in proteostasis might underlie protein aggregate 
formation in ZDF brains. We found both the expression and phosphorylation of mTOR and 
S6 ribosomal protein to be higher in ZDF brains. Phosphorylation of these proteins is 
necessary for protein synthesis. High glucose is known to stimulate mTORC1 to promote 
protein synthesis [50], which may represent one of the main causes of protein aggregate 
formation in ZDF brain. Indeed, mTOR inhibitors such as rapamycin protect against 
aggregate formation in taupathies [51]. In addition to mTOR activation, changes in the two 
major intracellular protein degradation systems, the autophagy-lysosomal and ubiquitin-
proteasome system [52] were observed. Our data suggest a blockade in the autophagy 
pathway, thus limiting protein turnover, in ZDF brain in view of the absence of transition of 
























LC3-I into LC3-II. Such blockade in autophagy is in line with the results in Alzheimer’s 
models, in which the induction of autophagy is known to lead to a massive accumulation of 
autophagy intermediates (vacuoles) with low levels of clearance [53] along dystrophic and 
degenerating neurites. In addition to its effect on autophagy, proteosomal breakdown of 
proteins seems also affected, as ZDF had higher expression of ubiquitinated proteins (UB-
proteins), which normally are processed by proteosomal degradation [54]. UB-protein 
aggregates increase in hyperglycemia and endoplasmic reticulum stress [19] and get 
accumulated in neuronal inclusions [55]. Curiously, UB-proteins accumulated in ZDF 
brains had a lower molecular weight compared to Lean, which might reflect the increased 
protein cleavage in ZDF brain. Taken together, in ZDF brains the protein synthesis 
machinery is activated while protein degradation is impaired, likely becoming the leading 
cause in the formation of protein aggregates. 
ROS damage to proteins exists in brain cells at high glucose levels [45,56] likely 
representing a second driving force for protein aggregation in diabetes. The presence of 
increased ROS in ZDF brain is evidenced by the decrease in FABP, and the increases in 
HIF1A and ROS production. Further, the increase in CML indicates impaired glucose 
metabolism and formation of oxidized amino acids in ZDF brains [48]. Thus, our results 
demonstrate that ROS production is likely increased in brain of ZDF rats. Oxidative stress 
might precede protein deposition [57], but conversely protein aggregates may also increase 
ROS formation and damage brain cells through oxidization of neuronal components [58] 
eventually leading to apoptotic or necrotic cell death [5]. Thus, a suitable antioxidant, 
potentially to some degree inhibits the damage present at high glucose concentrations. 
Additional loss of oxidant defense also would amplify the detrimental effects of ROS. 
Amongst all the antioxidants that are available in the body, thiols constitute the major 
portion of the total body antioxidants and they play a significant role in defense against 
reactive oxygen species [59]. Here our data show for the first time that the levels of CBS, 
one of the main H2S producing enzymes in brain, and thiol content are significantly lower 
in ZDF brains. 
Treatment with NaHS decreased protein aggregates in cultured slices of ZDF frontal brain. 
Higher glucose levels (35 mM) in culture medium provided a suitable in vitro model for the 
experiments, first because according to our previous experiment we found a lower glucose 
level (25 mM) to diminish the number of protein aggregates in vitro and second because 
higher glucose levels are known to decrease H2S levels [60]. We have previously shown 
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that NaHS modulates mTOR activity and inhibits ROS production in aging Werner 
syndrome skin fibroblasts while inhibiting protein aggregation in these cells [28]. 
Moreover, the induction of free thiol groups in an organism might have an important role in 
delaying the aging process [61]. This research is the first report pointing to the therapeutic 
potential of H2S as NaHS in protecting against protein aggregation in brain. H2S may exert 
its protective effect through various mechanisms. First, H2S possesses antioxidant 
properties and administration of NaHS inhibits reactive oxygen species, and the deposition 
of ECM (extracellular matrix) components in diabetic rats [62]. Indeed, NaHS treatment 
upregulated HIF1A in brain slices, potentially protecting cells against oxidative stress while 
increasing glucose tolerance/metabolism and mediating a neuroprotective response [63]. It 
is important to note that according to the presented data, having anti-oxidant properties is 
not enough for a substance to lower protein aggregates in ZDF brain to Lean levels, as 
NAC which is known to have strong antioxidant activity, inhibited ROS formation but did 
not show the full beneficial effects of NaHS in lowering protein aggregates. Thus, these 
results suggest the presence of additional mechanism involved in the beneficial action of 
NaHS, although ROS inhibition is most probably an important factor. Secondly, H2S may 
act through inhibition of the mTOR pathway. We found H2S to inhibit protein synthesis by 
inhibition of mTOR as also shown previously in kidney cells [50]. A third mechanism of 
action of H2S may constitute of regulation of autophagy. We found H2S supplementation 
to regulate and lower LC3-I expression in ZDF brain. H2S treatment led towards higher 
autophagy as shown by LC3-II/LC3-I ratio. The increase in Sirt-1 levels and Sirt-1 
phosphorylation could be another important indicator of higher autophagy levels through 
H2S treatment [28]. As NaHS normalized proteostasis in ZDF brains by inhibiting protein 
synthesis and gene expression, it would be conceivable that the regulation of autophagy by 
H2S represents a lowered flux of defective proteins to the autophagy pathway. Finally, an 
effect of H2S on cellular metabolism may convey beneficial effects in diabetes. 
Hyperglycemia is known to inhibit AMP kinase (AMPK) activity leading to cellular 
damage [64], H2S has the potential to preserve mitochondrial function [65] via regulation 
of mitochondrial ATP-sensitive potassium channel, p38 mitogen-activated protein kinase 
and c-Jun NH(2)-terminal kinase pathway. Consequently, H2S potentially constitutes a 
suitable treatment against hyperglycemia induced cell damage in case the above pathways 
are affected [66]. Moreover, H2S has been shown to regulate proteostasis in diabetic 
animals through activation of AMPK [50]. Interestingly, H2S also potentiates the function 
























of NMDA-glutamate receptors implicated in long term memory, while protecting proteins 
against nitration or oxidation [67]. Thus, H2S exerts different protective effects which seem 
to be of importance in the protection of brain tissue from hyperglycemia stress and protein 
aggregation. The changes in the expression of several proteins probably involved in high 
glucose induced protein aggregation in ZDF brain and the effect of NaHS on protein 
aggregation and protein expression in ZDF brain are summarized in Table 2. 
 
Table 2. Summary of changes in several important parameters involved in high glucose induced protein 
aggregation in ZDF brain and the effect of NaHS on them. 
 
Although ZDF animals displayed both an increase in non-fasting blood glucose levels and 
HbA1c, it should be noted that the development of overt diabetes was considerably slower 
in this batch of ZDF than observed in our previous experiments in the same animal strain 
[68]. While the reason for this remains elusive, in view of the current data, the animals 
would be best defined as being pre-diabetic. 
This study identified the presence of protein aggregation and its key mechanistic targets in 
ZDF brain and found it to coincide with lowered brain thiol levels and lowered CBS 
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expression. In addition, we demonstrate for the first time that the administration of H2S 
donor, NaHS, diminishes protein aggregation in the brain. Although we have presented 
several hypothesis in regards to possible mechanism by which H2S inhibits protein 
aggregation in ZDF brain, our goal here was not to establish a mechanism of action for H2S 
treatment but rather to show that H2S inhibits protein aggregates in ZDF brains. This study 




Animals, glucose measurement and sample preparation 
Male Zucker diabetic fatty rats (ZDF, n = 8) and control rats (Lean, n = 8) were obtained 
from Charles River Laboratories at 6 weeks of age with an average weight of 266 g for 
ZDF and 203 g for Lean. The animals were fed water and chow ad libitum throughout the 
experiment till they reached 17 weeks of age. Blood samples were taken every two weeks 
from week seven to week seventeen. Glucose and HbA1c levels were measured by 
commercial kits (Roche). At 17 weeks of age, rats were anesthetized by 2.5% isoflurane 
and sacrificed by exsanguination. Brains were removed and either snap frozen in liquid 
nitrogen or cut into 200 μm thick slices using a McIlwain tissue chopper and placed in 
brain nutrition medium/neurobasal medium (Gibco BRL, Cat. No. 21103–049) for in vitro 
experiments. The concentration of glucose in frontal brain homogenates was measured 
using Accu-Check Aviva (Roche diagnosis, Mannheim, Germany) in which a drop of 
homogenized brain (n ≥ 5 samples in each group) was placed on the glucose test strip and 
read by the instrument. All experiments were approved by the Animal Care Committee of 
the University Medical Center Groningen (Dec 6032B). 
 
Brain section treatment 
To study frontal brain slices in culture, 200 μm thick brain slices were placed in brain 
nutrition medium/neurobasal medium with 25 mM D-glucose and supplemented with 10% 
fetal bovine serum and 0.5 mM L-glutamine. As higher glucose levels are suggested to be 
responsible for the lower baseline levels of H2S detected in the medium of cells [60] the 
above medium was supplemented to a total of 35 mM glucose to create a high state of 
hyperglycemia, an environment more similar to what is observed in vivo. In treated slices, 
50 μM NaHS was added to the wells every 10 h until the completion of the experiment at 
























two days of culture. The final concentration of H2S in culture medium after the addition of 
50 μM NaHS lies in the normal range of brain H2S levels found in rats, i.e. between 50 and 
160 μM [69]. In all our experiments, NaHS was used at a concentration of 50 μM, as pilot 
experiments showed this concentration to promote the highest level of cell survival in 
cultured brain tissue sections according to caspase 3/7 activity assay results, as also 
previously found by others [69]. Controls did not receive NaHS in the medium. NAC (N-
acetyl-L-cysteine) 100 μM, which is the highest achievable concentration in plasma with 
tolerable oral dosing of NAC, was used to treat brain slices as additional controls to study 
the effect of a frequently used “antioxidant” in vitro, on ROS levels and protein aggregation 
in ZDF brains. Brain slices were kept in culture for two days, washed with PBS (phosphate 
buffered saline) and snap frozen in liquid nitrogen for either tissue staining or Western blot 
analyses. 
Antibodies and Western blot analysis 
Antibodies used were mouse carboxymethyl lysine (R&D system, MAB3247, UK), mouse 
mono- and polyubiquinilated conjugates (Enzo life Sciences BVBA, BML-PW1210-0025), 
LC3 (Cell signalling, 2775), B-FABP (Santa Cruz Biotechnology; FL-132; Sc-30088), 
fibronectin (Santa Cruz, sc-6952), CBS (Santa Cruz SC-46830), phospho-mTOR (Millipore 
15–105 Pathway Explorer Anti-phospho-mTOR ser 2448), p-S6 ribosomal protein 
(S235/236 Cell Signaling D57.2.2E), S6 ribosomal protein (Cell Signaling (5G10) 2217), 
HIF1A (Santa Cruz, sc-13515), total phosphorylation independent anti-tau (BR134, 
Cambridge, UK), phosphorylated tau protein (AT8 Ser202/Thr205, Innogenetics, 
Zwijndrecht, Belgium). Levels of hyperoxidized peroxiredoxins were assessed by Western 
blotting using rabbit anti-Prx-SO3 antibody (Abcam, ab16830). 
Western blot analysis was conducted to investigate protein expression in brain tissue. 
Frozen frontal brains were homogenized (20% w/v) in ice-cold RIPA lysis buffer (1% 
Igepal ca-630, 1% SDS, Roche protease and phosphatase inhibitor cocktail in PBS) [70]. 
The amount of protein was measured by Bradford assay and loading buffer (20 μl) was 
added to every 50 μg of protein and ran at 100 V for 70 min. Proteins were transferred to 
nitrocellulose membranes. To use the same membranes to detect different proteins and 
prevent possible loading interferences in presented data, the membranes were cut at specific 
places indicated by colored protein ladder, using a sharp surgical scalpel and probed using 
the appropriate antibody. Protein bands on antibody treated and washed membranes were 
detected by West Pico Chemiluminescent Substrate (supersignal), photographed by 
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GeneSnap (version 6.07; Syngene, Cambridge, UK) and analyzed with genetool software 
(version 3.08, SynGene, UK). Protein expression was corrected over β-actin as an internal 
reference. 
 
Measurement of protein synthesis in brain tissue 
To show the presence of active protein synthesis in ZDF brain and the effect of NaHS 
treatment on protein synthesis levels, the ratio of protein-to-DNA known as an indice of 
protein synthesis capacity, was calculated in each sample. Total genomic DNA was isolated 
from each brain sample using the Nucleospin Tissue Kit (Macherey-Nagel, Duren, 
Germany). The DNA concentration in each sample was measured using a NanoDrop 
spectrophotometer (Life Science ND1000, US). Protein concentration in each sample was 
measured using the Bradford assay. 
Real-time PCR (qPCR) 
In addition to Western blot analysis, the expression of fibronectin, tau and CBS in brain 
slices was analyzed by qPCR. In brief, RNA was extracted from each sample using the 
Nucleospin tissue kit (Cat NO. 740955.250 Macherey-Nagel, UK). RNA (1 μg) was 
reversely transcribed in a reaction mixture (20 μl) containing 1 μl of random hexamers, 0.5 
μl of RNase inhibitor, deoxynucleotide triphosphates (0.2 μl), 1 μl of reverse transcriptase, 
4 μ l RT buffer and Tris buffer (pH 7.4) at 37°C. Specific primers to rat Fibronectin 
(Forward: AGAGCATACCTCTCAGAG and Reverse: CTGCTCATCAGTTGGGAA), rat 
total tau (Forward: TGACACGGACGCTGGCCTGAA and Reverse: 
CACTTGGAGGTCACCTTGCTC), Cystathionine beta synthase (Forward: 
ATGCTGCAGAAAGGCTTCAT, Reverse: GTGGAAACCAGTCGGTGTCT) and β-actin 
(Forward: AAGATGACCC AGATCATGTTTGAG and Reverse: 
ACGTACATGGCTGGGGTGTTG) were synthesized (Base Clear, Netherland). SYBER 
green qPCR was performed using Bio-rad CFX384 C1000 (USA, CA) and data were 
quantified by Bio-rad CFX manager 2.0 using reagents from the SYBR Green PCR-Master 
Mix (Qiagen, Hombrechtikon, Switzerland). The samples in PCR 384 well plate were 
transferred to the thermal cycler and applied to the following protocol: predenaturation at 
94˚C (5 min; 1 cycle) followed by 35 cycles of denaturation at 94˚C (30s), annealing at 
57˚C (30 s), extension at 72˚C (45 s) and a final extension at 72˚C (8 min; 1 cycle), 
followed by a melting curve. All cycle threshold (Ct) values were collected at the 
exponential phase of the qPCR. All data were normalized to β-actin. 
























Histochemistry and microscopy 
Flash frozen frontal brains were cut at 15 μm thickness using a cryostat (Leica CM-1800, 
Chatsworth, CA) at -20°C. Tissue sections were thaw-mounted onto VistaVision 
HistoBond adhesive slides. The Bielschowsky silver impregnation was performed to 
reliably stain protein aggregates forming the neurofibrillary tangles [71]. To perform 
Bielschowsky silver stain, the rehydrated brain sections mounted on slides were covered 
with 20% AgNO3 and incubated at room temperature in the dark for 20 min. The solution 
was washed off with distilled water and replaced by ammoniacal silver solution for 20 min 
in the dark. Then, the solution was tipped off and the slides were immersed in ammonia-
water (four drops of ammonia added to 100 ml distilled water). Subsequently, slides were 
incubated in ammoniacal silver solution with developer (100 ml distilled water, 20 ml 
formaldehyde, 50 μl concentrated HNO3 and 0.5 g citric acid) to develop the silver stain for 
3–6 min. The quality of stain was controlled under the microscope (aggregates were dark 
brown/black with cluster like conformation). The sections were then immersed in ammonia 
water for 1 min and then washed twice in distilled water. The reaction was stopped using 
5% hypo-sodium thiosulphate for 5 min. Sections were rinsed, dehydrated, cleared and 
mounted by resinous medium. Aggregates were counted in the frontal brain sections. Ten 
random fields per slide of brain from four animals in each group were examined. 
For immunohistochemistry analysis the mounted sections on slides were subjected to 
graded ethanol rehydration (100–60%) and brought to water. Hydrogen peroxide activity 
was blocked for 1 h in peroxidise-blocking buffer (Dako, Denmark, S2023). The sections 
were then incubated for 1 hr at 37°C with the primary antibodies (1:100 in PBS containing 
1% BSA (bovine serum albumin) and 1% rat serum) at room temperature. The slides were 
washed with PBS, followed by addition of the specific secondary antibodies either 
fluorescent or non-fluorescent (1:100 in block buffer containing 1% BSA and 1% rat 
serum) for 1 h at room temperature. Slides were then washed in PBS thrice. Dako mounting 
medium was incorporated to visualize the nuclei and fix the glass coverslips on fluorescent 
stains. For non-fluorescent stains AEC (3-Amino-9-Ethylcarbazole) + High sensitivity 
substrate chromogen (Dako, Denmark k3469) was used to visualize the stain while the 
nuclei were stained by hematoxylin counter staining. Non-fluorescent stains were then 
washed in tap water and coverslips were fixed using an aqueous mounting medium (Dako). 
Measurement of reactive oxygen species in brain 
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Oxygen radicals were determined by a fluorometric method using fluorogenic CM-H2-
DCFDA (2,7 dichloroflourescein diacetate). 10 μl of each tissue sample in RIPA was 
loaded into a 96-well FluoroNunc black Plate. 150 μl of 0.1 M phosphate buffer (pH 7.4) 
and 10 μl of CM-H2-DCFDA (2,7 dichloroflourescein diacetate) in methanol was added to 
each well. The plate was incubated in a water bath (37°C) for 30 min and centrifuged at 
12,000 × g for 8 min. Fluorescence was measured with a Hitachi fluorescence spectrometer 
at an excitation wavelength of 488 nm and an emission wavelength of 525 nm. Auto 
fluorescence was subtracted prior to DCF fluorescence [72]. 
Assessment of intracellular thiol groups in brain 
Total levels of cellular thiol groups (−SH) in Lean and ZDF brain samples were measured 
based on the reduction of 5,5 dithiobis-2-nitrobenzoic acid (DTNB, Sigma). Brains were 
lysed in 10 mM Tris-buffer 1% Triton X-100 (Sigma), followed by centrifugation at 7000 × 
g for 10 minutes. The supernatant was incubated with phosphate buffer containing DTNB 
at room temperature for 60 minutes. The quantification was conducted at 412 nm using a 
microplate reader. 
Statistical analysis 
The statistical analyses was based on the analysis of ten slices each from four animals using 
the One-way ANOVA with Tukey’s test or unpaired student t-test with Welch’s correction. 
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Metformin is proposed to confer vascular benefits beyond glycemia control. This may 
include pleiotropic improvement of endothelial function, possibly via a suggested 
mechanisms involving increased GLP-1. In type-1 diabetes mellitus (T1DM) patients, 
metformin indeed improved flow-mediated endothelium-dependent relaxation (EDR), but 
at the same time increased prostglandin (PG)-F2α levels, a known endothelial contracting 
factor contributing to impaired EDR. To explain this seemingly paradoxical finding we 
hypothesized that metformin increases other endothelial vasodilator mediators (e.g. NO and 
EDHF) to an even larger extent. 
To study this, spontaneously hypertensive rats (SHR) were employed which display 
impaired EDR involving contractile PGs. EDR was studied in isolated aortas using 
inhibitors to assess the involvement of PGs, NO and EDHF. 12-week metformin treatment 
(300 mg/kg/day) improved aorta EDR by up-regulation of NO and particularly EDHF; it 
also reduced blood pressure and increased plasma sulphide levels (a proxy for H2S, hence a 
possible mediator of EDHF). Moreover, these effects persisted in SHR with streptozotocin 
(STZ)-induced T1DM. We similarly studied the effect of vildagliptin, which targets the 
incretin axis by increasing GLP-1 via inhibition of DPP-4. Vildagliptin (10 mg/kg/day) also 
reduced blood pressure and improved EDR in aorta of SHR, but not STZ-SHR, mainly via 
the inhibition of contractile PGs. Neither metformin nor vildagliptin altered blood glucose 
or HbA1c. 
Metformin reduces blood pressure and improves EDR in SHR aorta via up-regulation of 
NO and particularly EDHF, an effect that was independent from glycemia control and 
maintained during T1DM. A comparison to vildagliptin did not support effects of 
metformin mediated by GLP-1 but rather highlighted differential mechanisms by which 






























Metformin is an effective oral anti-diabetic drug, which decreases hepatic glucose 
production and increases peripheral glucose uptake in skeletal muscle. The UK Prospective 
Diabetes Study (UKPDS) established cardiovascular benefit and improved survival in  
metformin treatment compared with conventional treatment in overweight type-2 diabetes 
mellitus (T2DM) patients [1]. Given that the glucose-lowering effects of metformin, 
sulphonylurea and insulin in UKPDS were similar, it has been proposed that metformin 
confers additional vascular benefits beyond those of glycaemia control alone [2,3]. DM 
often coexists with hypertension (HT) [4,5] and the results of large clinical studies suggest 
that the benefits of tight blood pressure control in T2DM patients are as important or may 
be even greater than the benefits of a more intensive glycemia control [6,7]. Some clinical 
studies have reported a blood pressure lowering effect of metformin [8-10] although others 
reported the lack of such effects [11-12]. 
Clinical studies reporting on metformin treatment associated with the improvement of 
endothelial function appear more consistent [13-15]. This is of interest because endothelial 
dysfunction is considered among the earliest vascular abnormalities induced by 
cardiovascular risk factors and a strong predictor of cardiovascular events in several patient 
groups [16]. In a study by Mather et al. [13] in T2DM patients, metformin improved both 
insulin-resistance and acetylcholine-stimulated flow, with a strong statistical link between 
these variables. In another study, long-term metformin in T2DM subjects improved certain 
circulating markers of endothelial function independently from changes in HbA1c, insulin 
dose and weight, which may explain why it is associated with a decreased risk of CV 
disease in these patients [14]. 
Metformin has also been investigated in type 1 (T1) DM patients, but only one study 
assessed its effects on endothelial function [17]. In that study, 6-months of metformin 
treatment, in addition to a basal-bolus regimen of insulin, in uncomplicated T1DM patients 
resulted in a significant improvement of flow-mediated dilation (FMD), a marker of 
systemic endothelial function. At the same time however, metformin increased 
prostaglandin (PG) F2α in these patients which seems 'paradoxical' because PGF2α is a 
marker of oxidative stress products, known to negatively affect endothelial function. 
Together with PGH2 and thromboxane A2 (TxA2), PGF2α is a potent vasoconstrictor 
prostanoid derived from endothelial cyclooxygenase (COX) and known to oppose 
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endothelium-dependent relaxation (EDR) [18]. One possibility to explain the improved 
FMD response after metformin in face of increased (contractile) PGF2α may be that 
metformin increased other endothelial vasodilator mediators such as nitric oxide (NO) 
and/or endothelium-derived hyperpolarizing factor (EDHF) to an even larger extent. 
Spontaneously hypertensive rats (SHR) constitute a model of endothelial dysfunction 
involving increased production of endothelial COX-derived contracting factor(s) in a 
setting of HT [18,19]. In the present study, streptozotocin (STZ) was used to induce DM in 
SHR to further investigate the treatment effects of metformin on endothelial dysfunction in 
hypertensive T1DM. Diabetic and non-diabetic SHR received metformin for 12 weeks or 
remained untreated after which blood pressure was assessed and the isolated aorta studied 
for different endothelial mediators involved in EDR. Interestingly, metformin was recently 
shown to increase glucagon-like peptide-1 (GLP-1) concentrations and GLP-1 receptor 
expression in mouse islets in a PPARα-dependent, AMPK-independent mechanism [20], 
thus suggesting a role for the incretin axis in mediating some of the effects of metformin. 
To explore this, additional comparisons were made to SHR treated with vildagliptin. 
Vildagliptin is an anti-diabetic drug which targets the incretin axis by increasing GLP-1 via 
inhibition of the enzyme dipeptidyl-peptidase 4 (DPP-4) [21]. Vildagliptin has also been 
shown to improve endothelium-dependent vasodilation in T2DM patients [22] but its effect 
on endothelial dysfunction in (hypertensive) T1DM has not been studied previously. 
 
2. Materials and Methods 
2.1 Animals and study design 
The protocols for animal care and use were in accordance with EU Directive 2010/63/EU 
for animal experiments and approved by the Committee for Animal Experiments of the 
University of Groningen (Permit Number: DEC6032E). Studies were conducted using male 
SHR rats (n=43) obtained from Charles River (France). Animals were housed group-wise 
in standard cages and maintained on a 12:12-hour light:dark cycle with free access to 
normal standard rat chow (Hope Farms B.V., Woerden, Netherlands) and normal tap 
drinking water throughout the study. 
After one-week acclimatization when animals were at 7 weeks of age (150-200 g), a blood 
sample was drawn from the tail vein. After assessment of baseline parameters rats were 
injected either with saline or 60 mg/kg i.p. STZ to induce T1DM [23]. This was followed 
one week thereafter by the determination of blood glucose (after 3 hour fasting) based on 






















which STZ and non-STZ rats were stratified to treatment with 300 mg/kg/day metformin 
[24], 10 mg/kg/day vildagliptin [25] or no treatment. Starting at 8 weeks of age, treatments 
were initiated and maintained until sacrifice at 20 weeks of age. Treatments were provided 
via the drinking water and the amount of drug adjusted weekly according to body weight 
and water intake. When required, individual rats were provided an insulin implant 
(Linplant, Linshin Inc, Canada) to prevent excessive loss of body weight and maintain 3 
hour fasting blood glucose levels within a target range of 16-28 mmol∙L-1 in accord with 
Lim et al. [26]. Since blood samples were obtained during mild anesthesia (2% isoflurane 
in oxygen) and immediately assessed for 'bed-side' glucose levels, subcutaneous placement 
of the insulin implant (required in 3/7 STZ-SHR, 4/7 STZ-vildagliptin and 3/7 STZ-
metformin rats at 2 or 4 weeks after STZ) was performed during anesthesia at the same 
time. 
Throughout the study period, 24h urine production and water intake was monitored weekly 
(metabolic cages), and a blood sample from the tail vein for blood glucose was collected 
every 2 weeks. The arterial blood pressure was determined indirectly by the tail-cuff 
method at the end of the study period. After twelve weeks of treatment (i.e. when animals 
were 20 weeks of age), rats were anesthetized (2.5% isoflurane in oxygen) and the kidney 
and liver removed and weighed. The aorta was also removed and prepared for studies of 
EDR in organ bath experiments. 
2.2 Aorta studies of endothelium-dependent relaxation 
The thoracic descending aorta was excised and placed in a Krebs bicarbonate solution of 
the following composition (mmol∙L-1): NaCl, 120.4; KCl, 5.9; CaCl2, 2.5; MgCl2, 1.2; 
NaH2PO4, 1.2; glucose, 11.5; NaHCO3, 25.0; continuously aerated with 95% O2 and 5% 
CO2. The vessel was cleaned of adhering fat tissue and rings of 2 mm in length were cut 
with a sharp razor blade, with care not to touch the luminal surface. Rings were mounted 
between two stirrups in organ baths filled with 15 ml of Krebs solution. One stirrup was 
anchored inside the organ bath and the other connected to a displacement transducer to 
determine isotonic changes, as described previously [27]. Rings were subjected to 14 mN 
and allowed to stabilize for 60 min before they were primed and checked for viability by 
evoking a contraction with 60 mmol KCl twice. After washout and renewed stabilization, 
rings were pre-contracted with 1 µmol∙L-1 phenylephrine (PE) followed by the 
determination of the dilatory response to the endothelium-dependent vasodilator 
acetylcholine (ACh: 10 nmol∙L-1 to 100 µmol∙L-1) both in the absence (i.e. vehicle) and the 
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presence of either 10 µmol∙L-1 indomethacin (INDO) alone (i.e. to inhibit COX-derived 
vasoactive eicosanoids), or in combination with 100 mmol∙L-1 NG-mono-methyl-L-arginine 
(L-NMMA, i.e. to additionally inhibit NO-synthase). 
2.3 Clinical chemistry 
Blood glucose was determined using an Accu-Check Aviva monitor (Roche Diagnostics, 
Almere, the Netherlands). HbA1c and urinary albumin were determined using a DCA 
Vantage Analyzer (Siemens Healthcare Diagnostics Inc., Deerfield, IL), and plasma 
triglycerides on a multitest analyzer system (Roche Modular; F. Hoffmann-La Roche Ltd., 
Basel, Switzerland). For assessment of plasma sulphide (as a proxy of H2S), sulphide 
antioxidant buffer was prepared and added to blood samples obtained from the rats in a 1:1 
ratio. An sulphide was immersed into the mixture and the electrode potential was monitored 
and the stabilized mV reading recorded. The sulphide ion concentration of the blood was 
read using electrode standardization curve prepared according to the manufacturer’s guide 
(Laser Research Laboratories, Inc. Los Angeles, CA, 90036 USA). 
2.4 Solutions and drugs 
Compounds for Krebs solution and aorta studies were obtained from Merck (Darmstadt, 
Germany) and from Sigma-Aldrich (St. Louis, MO, USA). Metformin (Metformine HCl, 
Pharmachemie BV) and vildagliptin (Galvus, Novartis) were obtained from the Hospital 
Pharmacy at the University Medical Center Groningen, the Netherlands).  
2.5 Calculations and data analysis 
Vasodilator responses to ACh were expressed as a percentage of PE-induced pre-
contraction before individual CR-curves were generated and the Area Under each 
individual Curve (AUC, in arbitrary units) determined (SigmaPlot, Systat Inc., San Jose, 
CA). The AUC was used to represent the individual response-size in a given condition, and 
where appropriate, to calculate the individual difference in response-size between different 
conditions (i.e. difference response-size in the presence of saline vs. INDO vs. INDO plus 
LNMMA for ACh). The AUC was also used to calculate and present the average response-
size per group, and for subsequent analysis of differences in response-size among 
experimental groups. For that matter, the INDO-sensitive part of the response was regarded 
to be mediated by COX-derived PGs, the LNMMA-sensitive part to be mediated by NO, 
and the INDO+LNMMA-resistant part to be mediated by EDHF. Hence, the preference for 






















AUC to present and analyze response-size rather than whole CR-curves was based on 
practical reasons and reasons of clarity only. 
Unless stated otherwise, all data are presented as mean ± SEM; n values represent the 
number of investigated rats or valid observations obtained for a given parameter. IBM 
SPSS Statistics for Windows, Version 20.0 (Armonk, NY: IBM Corp.) was used for 
statistical analysis. Full CR-curves were compared using repeated measurements ANOVA. 
Student's unpaired t-test was used to compare control SHR with STZ-SHR. One-way 
ANOVA followed by LSD post-hoc testing for multiple comparisons was used to test the 
effect of treatment in control SHR or in STZ-SHR. Linear regression analysis was 
performed to further analyze possible relationships between mediators of EDR and SBP. 
P<0.05 values were considered statistically significant. 
 
3. Results 
3.1 SHR rat characteristics 
3.1.1 Effect of STZ in untreated SHR 
Injection of SHR with STZ at the start of the study typically induced changes related to the 
development of DM. These included a significant increase in blood glucose, a reduced gain 
in body weight despite increased food intake, and increased urine production and water 
intake (Figure 1). Twelve weeks after induction of T1DM at the end of the study period, 
STZ-SHR had increased blood HbA1c and triglycerides, and showed early signs of 
development of end-organ damage. That is, relative liver and kidney weight were 
significantly increased compared to control SHR, as was urinary albumin excretion (Table 





























3.1.2 Effect of treatments 
Treatment with vildagliptin or metformin did not alter blood glucose (Figure 1A), HbA1c 
and triglycerides (Table 1), neither in control SHR nor in STZ-SHR. Vildagliptin tended to 
decrease the gain in body weight, and increase the production of urine and water intake in 
STZ rats during the treatment period, but at the end of the study period this was not 
significantly different from untreated STZ-SHR (Figure 1). In contrast, metformin 
significantly reduced the gain in body weight, as well as the urine production and water 
intake in STZ rats. This effect was consistent over the whole study period and to some 
extent (i.e. urine production and water intake) also visible in non-STZ rats (Figure 1). 
Metformin additionally reduced SBP both in SHR and STZ-SHR rats (Table 1). Blood 
pressure lowering effects were also observed after vildagliptin although statistically 
significant reduction in SBP was obtained in SHR only, but not STZ-SHR (Table 1). 
Finally, metformin raised urinary albumin excretion in STZ-SHR, albeit not significantly, 




Figure 1. Effects of vildagliptin and metformin on SHR characteristics. Eight week old spontaneously 
hypertensive rats (SHR) rats were injected at t=0 with streptozotocin (STZ, 60 mg/kg) or saline (non-STZ) to 
induce type-1 diabetes mellitus or not before they were treated for 12 weeks either with vildagliptin (10 
mg/kg/day) or metformin (300 mg/kg/day), or remained untreated. Shown are the overtime effects on (A) blood 






















glucose, (B) body weight, (C) food intake, (D) urine production and (E) water intake. Data are mean ± SEM (n=6-
8 for each group). *indicates p<0.05 vs. untreated (STZ-)SHR at a specific time point; #indicates p<0.05 vs. 
untreated (STZ-)SHR for the whole curve. 
 
3.2 Endothelium-dependent relaxation (EDR) to acetylcholine in SHR aorta 
3.2.1 Effect of STZ in untreated SHR 
Full ACh-induced CR-curves in the absence of inhibitors are shown in Figure 2 together 
with their respective AUC. ACh typically induced a biphasic response showing relaxation 
at the lower concentrations and contraction at the higher concentrations [19]. This pattern 
appeared slightly more outspoken in STZ-SHR (Figure 2B) compared to control SHR 
(Figure 2A) but net relaxations did not significantly differ between both groups: i.e. not in 
terms of maximum relaxation (to 71±5% vs. 61±5% of pre-contraction level, t-test p=0.18) 
nor when the whole CR-curve (repeated measures ANOVA p=0.47) or the AUC (170±19 
vs. 192±18 arb. unit, t-test p=0.43 ) was compared. 
Consistent with literature [19], inhibition of COX-derived vasoactive eicosanoids by pre-
incubation with INDO prevented the 'upstroke' at the higher concentrations of ACh (data 
not shown as a CR-curve), thereby increasing net relaxation by ~25% (AUC from 181±13 
to 225±12 arb. unit, paired t-test p=0.007) for untreated SHR and STZ-SHR combined. 
Induction of T1DM tended to increase the involvement of contractile PGs (from 30±25 arb. 
unit in SHR to 59±10 arb. unit in STZ-SHR) but this was not significant (t-test p=0.299). 
At the same time T1DM evoked an up-regulation of opposing NO-influence (from 74±25 
arb. unit in SHR vs. 139±7 arb. unit in STZ-SHR; t-test p=0.030), while the involvement of 





Figure 2. Effects of vildagliptin and metformin on endothelium-dependent relaxation in SHR aorta. Eight 
week old spontaneously hypertensive rats (SHR) rats were injected at t=0 with streptozotocin (STZ-SHR, 60 
mg/kg) or saline (SHR) to induce type-1 diabetes mellitus or not before they were treated for 12 weeks either with 
vildagliptin (10 mg/kg/day) or metformin (300 mg/kg/day), or remained untreated (control). Shown are the 
concentration-response curves of acetylcholine- (ACh-)induced relaxation in isolated aorta preparations obtained 
at the end of the study period for A) SHR and B) STZ-SHR rats, as well as C) the corresponding area under curve 
(AUC). Data are mean ± SEM (n=6-8 for each group). *indicates p<0.05 vs. control for the whole curve in panel 
A and B; #indicates p<0.05 vs. control in panel C. 
3.2.2 Effect of treatments 
In control SHR, treatment with vildagliptin profoundly increased net ACh-induced 
relaxation as compared to those untreated (Figure 2C). This increased response was largely 

































































































*p<0.05 vs. Control (repeated measures ANOVA)
#
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#p<0.05 vs.Control (t-test for multiple comparison)






















enhancing effect was mainly attributable to an increased involvement of COX-derived 
dilatory PGs after vildagliptin (Figure 3A). Similarly, metformin treatment also improved 
net relaxation to ACh (Figure 2C). Contrary to vildagliptin treated rats however, ACh-
induced relaxation in metformin treated animals increased in the presence of INDO (Figure 
3A), suggesting that metformin did not affect contractile PGs. Instead, the enhancing effect 
of metformin treatment on net ACh-induced relaxation in SHR was fully attributable to an 




Figure 3. Effect of vildagliptin and metformin on endothelial mediators in SHR aorta. Acetylcholine-induced 
relaxation was studied in the absence or presence of indomethacin and/or LNMMA after which the area under the 
curve (AUC) was determined and used to calculate the contribution of prostaglandins (PGs, sensitive to COX-
inhibition), nitric oxide (NO, sensitive to eNOS-inhibition) and EDHF (resistant to COX- plus eNOS-inhibition) to 
total relaxation (see also methods). Panel A and B shows the results for SHR and STZ-SHR, respectively. Data are 



































































































The above enhancing effects of metformin treatment on EDR seemed largely maintained 
when T1DM was induced. That is, the profile of ACh-induced relaxation was not 
significantly altered when STZ was used to induce T1DM in SHR (compare panels A and 
B in Figure 3). In contrast, the enhancing effect of vildagliptin treatment on ACh-induced 
relaxation as seen in control SHR was dramatically undone in T1DM rats, resulting in  
vildagliptin no longer improving ACh-induced relaxation (Figure 2C). This appeared most 
crucially due to the loss of vildagliptin treatment to alter the involvement of contractile PGs 
in STZ-SHR (Figure 3B). Although EDHF was significantly up-regulated in STZ rats 
treated with vildagliptin, this was insufficient to improve net ACh-induced relaxation in 
SHR with T1DM (Figure 3B). A summary of the directional changes induced by the 
treatments is also provided in Table 2. 
 
Table 2. Summary of directional changes in endothelial mediators in acetylcholine-induced relaxation in 
SHR aorta: effect of treatments. 
 
Symbols indicate directional changes induced by treatments compared to untreated SHR and untreated STZ-SHR. 
Double symbols ↓↓ and ↑↑ indicate a significant decrease and increase, respectively. 
 
3.3 Linear regression analysis of EDR, SBP and plasma sulphide levels 
The only endothelial mediator involved in EDR significantly correlating with blood 
pressure was EDHF, such that a higher EDHF linearly correlated with a lower blood 




Figure 4. Linear regression analysis of endothelial mediators of aorta EDR with SBP. Shown are scatterplots 
for the contribution of, respectively, (A) prostaglandins (PGs), (B) nitric oxide (NO) and (C) EDHF with systolic 
blood pressure (SBP). Results of linear regression analysis are as indicated, with EDHF being the only mediator 
significantly correlated with SBP. 
 
As H2S has recently been identified as a new EDHF [28,29], we additionally assessed 
plasma sulphide levels (as a proxy of H2S) and also correlated these with EDHF and SBP. 
Sulphide levels were significantly increased after vildagliptin and in particular after 
metformin (Figure 5A). Interestingly, sulphide levels positively correlated with EDHF and 
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Figure 5. Plasma sulphide levels and its correlation with EDHF and SBP. Shown are (A) the average plasma 
sulphide levels (as a proxy of H2S) in treated and untreated SHR and STZ-SHR, and scatterplots of individual 
plasma sulphide levels with (B) EDHF contribution in aorta endothelium dependent relaxation and with (C) 
systolic blood pressure. Results of linear regression analysis are as indicated. 
4. Discussion 
The main finding of the present study is that treatment of SHR with metformin and 
vildagliptin (1) improved endothelial function and reduced blood pressure (2) 
independently of glycemia control, (3) yet via differential mechanisms as it appears. 
Metformin improved aorta EDR by up-regulation of NO and in particular EDHF without 
attenuating the involvement of contractile PGs, an effect that also persisted in SHR with 
STZ-induced T1DM. In contrast, improved EDR after vildagliptin treatment in SHR was 
mostly attributable to the inhibition of contractile PGs, an effect however that did not 
persist in STZ-SHR. The findings implicate that (1) metformin and vildagliptin both have a 























































































highlight the way their effects are achieved via different mechanisms, and (3) the 
effectiveness of vildagliptin herein being dependent on the specific conditions concerned. 
These findings seem of relevance to the treatment of HT-patients with DM since 
improvement of endothelial function and blood pressure reduction - whether it be achieved 
primary or secondary - are considered important targets for pharmacotherapy to prevent the 
high incidence cardiovascular morbidity and mortality in these conditions.  
SHR is a well-studied model of endothelial dysfunction involving increased contractile PGs 
[18,19]. To our knowledge only few studies have previously investigated the treatment 
effects of metformin in SHR but none of these assessed its effect on EDR. Moreover, the 
effects of vildagliptin so far have not been investigated in SHR at all. Verma et al. [30] in 
an early study observed that treatment of five-week old SHR with (500 mg/kg/day) 
metformin for 2 weeks decreased plasma insulin levels and attenuated the increase SBP 
without affecting the plasma glucose levels. Blood pressure reductions have also been 
reported in some clinical studies such as in non-diabetic, obese, hypertensive women 
receiving metformin [31] and with vildagliptin in T2DM patients inadequately controlled 
with metformin [32]. However, the findings in humans are not consistent and could not be 
dissociated from glucose lowering effects. In the present study, metformin and vildagliptin 
did not affect blood glucose levels and HbA1c in our (STZ-)SHR, thus implying that the 
observed treatment effects in the present study were independent of (hyper)-glycemia 
control. 
Metformin tended to increase contractile PGs (albeit not significant) yet up-regulated NO 
and in particular EDHF to a significantly larger extent, thereby profoundly improving net 
EDR. Since this effect persisted in STZ-SHR it may also provide an explanation for the 
'paradoxidal' findings by Pitocco et al.  [17] who observed improved FMD response in face 
of increased (contractile) PGF2α after metformin in T1DM patients. Very recently, Tsai et 
al. [33] reported that metformin may exert an anti-hypertensive effect in SHR by 
restoration of the ADMA-NO pathway. Increased NO bioactivity after metformin is also in 
agreement with the results of previous studies by Davis et al. [34] which suggested that 
metformin improves endothelial vascular function in DM by increasing AMPK-dependent, 
hsp90-mediated eNOS activation. 
In addition to NO, metformin has been shown to raise hydrogen sulfide (H2S) tissue 
concentration in various mouse organs [35]. This seems of relevance because H2S has been 
identified as a new EDHF that sulfhydrates potassium channels [28,29] and functions a 






















vasculoprotective factor [36]. Hence, up-regulation by metformin of H2S as an EDHF could 
account for the increased ACh-induced relaxation that was resistant to COX- and 
LNMMA-inhibition, and which positively correlated with plasma sulphide levels (as a 
proxy of plasma H2S levels) in the present study. Furthermore, administration of exogenous 
H2S has been shown to reduce blood pressure in STZ-SHR [37]. An up-regulation of H2S 
as an EDHF contributing to the anti-hypertensive effect of metformin - as suggested by the 
inverse correlations of EDHF and plasma sulphide levels with SBP in the present study - 
seems in agreement herewith. 
Finally, some studies have reported the ability of metformin to reduce vascular production 
of vasoconstrictor PGs, which is in contrast with our present findings [38,39]. However, in 
these studies a different rat model (i.e. fructose-overloaded rat of metabolic syndrome, aged 
OLETF rat model of T2DM) and/or vascular beds (e.g. mesenteric arteries) were used. 
Furthermore, the reduced vascular production of vasoconstrictor PGs may have been 
secondary to the reduction in hyperglycemia after metformin in those studies, but not in the 
present. Overall, there seems limited and/or controversial evidence for a (pleitropic) action 
of metformin to improve EDR via the inhibition of COX-derived contractile PGs. 
Although the effect of vildagliptin has not been investigated previously in SHR, our present 
findings seem in line with other studies suggesting that GLP-1 elevating or GLP-1 receptor 
activating agents may restore endothelial function and reduce SBP in SHR [40,41]. Liu et 
al. [41] previously reported sitagliptin to improve EDR in SHR renal arteries via a GLP-1-
dependent mechanism involving the restoration of NO bioavailability. Vildagliptin also 
improved EDR in the present study, albeit not via increased NO as it appeared. 
Nevertheless, study differences in, amongst others, the vessel type investigated (e.g. aorta 
vs. renal artery), experimental conditions employed (e.g. use of INDO or not) and the way 
endothelial mediators were assessed (e.g. functional measurement of EDR sensitive to 
eNOS-inhibition vs. a direct measurement of NO-production) are likely contributors to such 
apparent discrepancies, although without necessarily excluding each other. For that matter, 
our results do seem in line with another recent study of the aforementioned group in which 
they reported sitagliptin to restore endothelial function in SHR renal arteries and in 
angiotensin II-infusion induced hypertensive C57BL/6 mouse aorta via the up-regulation of 
uncoupling protein 2 (UPC2) in a GLP-1-dependent pathway, leading to a reduced 
production of reactive oxygen species and subsequent reduction of COX-2 expression and 
COX-2-derived endothelium-derived contractile factor(s) (EDCFs) [42]. Although we did 
Chapter 4 
 100 
not study UPC2 and COX-expression in the present study, our finding that vildagliptin 
improved EDR via the inhibition of COX-derived contractile PGs opposing net relaxation 
is in agreement herewith. 
Remarkable, the enhancing effect of vildagliptin on EDR was abolished when SHR had 
received STZ to induce T1DM. In seeming conjunction herewith, the anti-hypertensive 
effect of vildagliptin - although still present to some extent - no longer reached statistical 
significance in STZ-SHR, thus indicating that presence of T1DM importantly modulated 
the vascular/hemodynamic effects of vildagliptin. A lack of improvement of EDR after 
vildagliptin in a setting of endothelial dysfunction in DM is consistent with our previous 
findings in Zucker diabetic fatty (ZDF) rats, a model of T2DM that is also characterized by 
impaired aorta EDR due to COX-derived EDCFs albeit in a normotensive setting [43]. In 
that study, vildagliptin similarly "failed" to inhibit the opposing role of COX-derived 
contractile PGs and to improve EDR in ZDF rat aorta [43]. Notably however, both in that 
study in T2DM ZDF rats [43] as well in the present study in T1DM STZ-SHR, triglycerides 
were increased. And in both studies vildagliptin treatment did not improve EDR, nor the 
increased triglycerides levels in DM. Interestingly in this context is the study by Nathanson 
et al. [44] who ex vivo investigated the effect of exenatide - an GLP-1 analogue - on EDR 
in rat femoral artery. These authors performed a short term pre-incubation study of this 
conduit artery with intralipid to induce triglyceride-induced endothelial dysfunction and 
found that exenatide did not restore EDR [44], which is in general consistency with our 
present findings (i.e. from a treatment point of view). Additionally interesting is the fact 
that these authors noticed a concomitant "paradoxical" increase in eNOS activity following 
intralipid pre-incubation, but which apparently was insufficient to compensate and restore 
or improve EDR. In the present study, induction of TIDM also raised the NO-contribution 
(in STZ-SHR vs, SHR) in EDR, albeit not significant, but possibly as a counteractive 
mechanism (i.e. from a physiologic point of view). Nevertheless, what remains is the 
discrepancy between vildagliptin treatment effects on EDR between different 
pathophysiological conditions. 
The effects of metformin and vildagliptin on EDR in (STZ-)SHR aorta in the present study 
may be considered pleiotropic, i.e. taking into account the lack of effect on glycemia 
control, but not independent of blood pressure reduction. That is, given the fact that HT is a 
per se risk factor for endothelial dysfunction and vice versa, the present study does not 
dissociate between a blood pressure lowering effect facilitating the improvement of 






















endothelial function or the other way around. Given our present findings however, we tend 
to interpret the blood pressure lowering effects more as a result of the treatment's effects on 
vascular endothelial function rather than vice versa. Particularly the observed 
intercorrelationships in the present study between vascular EDHF, systemic sulphide levels 
and arterial SBP in the overall context of literature in our view add to this opinion. 
Nevertheless, we did not investigate whether the EDR-part resistant to combined eNOS- 
and COX-inhibition (denoted as EDHF) was actually mediated by H2S, nor can we exclude 
that metformin's treatment tendency to reduce body weight played some role herein. 
The results highlight that metformin and vildagliptin differed in their pleiotropic potential 
to improve endothelial function. I.e. both compounds improved net EDR in SHR yet via the 
mobilization of different endothelial mediators. It seems that inhibition of contractile PGs 
in SHR aorta may be an effect more related to GLP-1 since it was found in vildagliptin 
treatment only, but not metformin. On the other hand, both vildagliptin and particularly 
metformin increased (plasma sulphide and) EDHF. No study has previously investigated 
the chronic effects of gliptins on EDHF, and only one study investigated the acute effects of 
alogliptin in C57BL/6 mice aorta. That study concluded that acute DPP-4 inhibition 
modulates vascular tone through GLP-1 independent pathways that are NO and EDHF 
dependent [45]. Hence, when compared to vildagliptin the results of our study provide little 
or no support that metformin exerted its treatment effects via GLP-1. Interestingly, gliptins 
are increasingly used as an add-on to metformin in T2DM patients when metabolic control 
is not achieved [46]. Our present findings imply that metformin and vildagliptin improve 
endothelial function via different mechanisms but which might be complementary when 
given together. Whether this is the case and, if so, whether it contributes to a better organ 
protection as seen in experimental studies after combined vildagliptin plus metformin 
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The immunosuppressant drug and sphingosine 1-phosphate (S1P) analog FTY720 
(Fingolimod) exerts pleiotropic effects on the vasculature and the heart. In patients with 
multiple sclerosis, FTY720 leads to changes in blood pressure and transient bradycardia. 
The vascular effects of FTY720 have also been studied acutely in experimental studies but 
its long term effects on resistance artery function remain unknown. Here we investigated 
myogenic constriction and S1P induced contraction in small mesenteric arteries of rats 
chronically treated with FTY720. 
Healthy Wistar rats received FTY720 1mg/kg/daily for six weeks. At termination, blood 
pressure was recorded and small mesenteric arteries collected for vascular studies in a 
perfusion set up. 
Myogenic constriction to increased intraluminal pressure was low, but the addition of S1P 
profoundly augmented vascular constriction in arteries of both controls and animals 
chronically treated with FTY720. Interestingly, endothelial denudation completely blocked 
the response to S1P in arteries of FTY720 treated animals, but not in those of control rats. 
In acute experiments, presence of FTY720 significantly augmented the contractile response 
to S1P, an effect that was partially abolished after the inhibition of cyclooxygenase (COX-
)-derived prostglandins. In experiments with cultured human endothelial cells, prolonged 
incubation with FTY720 abolished the expression of the S1P1 receptor subtype while 
leaving S1P2 receptor expression unaffected. 
In conclusion, long term treatment with FTY720 leads to a down-regulation of  smooth 
muscle cell reactivity to S1P, which, however, is compensated by the up-regulation of 
endothelial cell reactivity to release a contractile factor(s). The latter may include S1P-
induced release of contractile prostaglandins via mechanism in which chronic FTY720 
treatment down-regulates endothelial S1P1 receptor expression while preserving S1P2 
receptor expression.   






















FTY720 (fingolimod) is an analog of sphingosine 1-phosphate (S1P) that acts as an 
immunosuppressive agent by inhibiting the egress of lymphocytes from secondary 
lymphoid organs to peripheral blood [1,2] and treatment with FTY720 has been 
demonstrated effective in patients with multiple sclerosis (MS), autoimmune disease and 
organ transplantation [3]. The effects of S1P are mediated through specific G protein-
coupled S1P receptors of which five different receptor subtypes have been identified: 
S1P(1-5). Several agonists to these receptors have been developed and FTY720 has been 
identified as a relatively non-selective agonist which binds to S1P(1-5) [4]. However, the 
phosphorylated form of FTY720 has no affinity to S1P2 [5].  
Apart from its immunomodulatory role, FTY720 has profound effects on the cardiovascular 
system and administration of S1P and FTY720 is known to induce bradycardia both in 
human and in rodent animal studies [6]. FTY is known to act directly on the heart and the 
effects of FTY720 on heart rate are thought to be mediated mainly through S1P3, as 
selective S1P1 agonists did not induce bradycardia in mice and genetic deletion of the S1P3 
subtype resulted in the abrogation of S1P induced bradycardia [7].  
In the vascular endothelium, S1P1 is the most predominant subtype of S1P receptor and 
stimulation of endothelial S1P1 causes vasodilation in arteries through an increase in the 
production of NO [8]. In addition, S1P3 may also stimulate endothelial NO production, as 
S1P still elicits NO production following knock down of S1P1 [8,10]. In addition to S1P1 
and S1P3 receptors, the endothelium expresses S1P2, of which expression is increased in 
atherosclerosis and diabetes [11,12]. The effects of S1P2 activation include the induction of 
pro-inflammatory responses in endothelial cells, regulation of microvascular permeability 
and stimulation of angiogenesis [12]. However, S1P1 and S1P2 show opposing effects on 
vascular permeability, indicating that the homeostasis of microvascular permeability may 
be regulated by their balance [13].  
In contrast to the endothelium, the role of S1P receptors is less well understood in the 
vascular smooth muscle layer. Smooth muscle cells obtained from rat aorta predominantly 
express S1P2 and S1P3 and stimulation of these receptors activates several intracellular 
messengers including Rho kinase, intracellular calcium and MAPK [14]. Selective S1P3 
antagonism induced relaxation of dog cerebral arteries that were pre-contracted with S1P 
and decreased S1P induced calcium signaling in cultured human coronary artery smooth 
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muscle cells, while selective S1P2 antagonists were without effects [15]. However, S1P2 
antagonism has also been reported to inhibit S1P induced contractions of cultured coronary 
artery smooth muscle cells [16]. A further role for S1P2 receptors in vascular contraction 
has been demonstrated in mice genetically deleted of S1P2, resulting in impaired 
contractions to phenylephrine and KCl in mesenteric and renal resistance vessels [17]. In 
addition, a lack of S1P2 receptor induces decreases myogenic response, which is governed 
by TNFα in proximal cerebral arteries [18]. As FTY720/fingolimod is entering the clinic, a 
proper understanding of its vascular action upon chronic treatment seems warranted. 
Moreover, characterization of the effects of chronic treatment with fingolimod likely 
enhances our understanding of the diverse roles of S1P receptors in the vascular system, 
which may lead to improved and more specific therapies in cardiovascular disease. As 
FTY720 is known to affect all S1P receptors but S1P2, we hypothesized that long term 
FTY720 treatment alters the balance of vascular S1P signaling in the microvasculature, 
leading to altered vascular function. We, therefore, investigated vascular function of 
mesenteric arteries of rats to pressure and response to S1P after that were treated with 
FTY720 for six weeks. 
 
Materials and methods  
Animals and Study Design 
The experiments were performed according to the NIH Guideline for the use of laboratory 
animals and were approved by the research ethics committee at the University of 
Groningen. Twelve male Wistar rats from Harlan weighing between 180-200 gr were 
randomly assigned to control or FTY720 treatment. Rats in the active treatment group 
received daily 1 mg/kg body weight FTY720 (Novartis, Switzerland) via drinking water for 
6 weeks. A week prior to treatment, animals were housed under standard conditions for 
acclimation at the animal facilities of the University of Groningen. During the study, ad 
libitum food and tap water were provided. After six weeks of treatment, rats were 
anesthetized with 2.5% isoflurane in oxygen and data of hemodynamic function recorded 
by a pressure transducer catheter, which was inserted into the carotid artery (Datex-
Ohmeda, Cardiocap/5, USA). Afterwards, mesenteric arteries were isolated and transferred 
in normal physiologic saline for further studies.  
 




















Vascular reactivity of mesenteric arteries 
A third order branch of the superior mesenteric artery with a diameter of 249±3 µm, was 
dissected from surrounding fat tissue and mounted in a perfusion set up for pressurized 
vessels (Living System Instrumentation, Burlington, VT, USA). To evaluate the luminal 
diameter of the vessels, an inverted light microscope attached to a video camera and video 
dimension analyzer was integrated in the setup. The vessel chamber in the setup was filled 
and continuously recirculated with warmed (37°C) and oxygenated (5% CO2 in O2) Krebs 
solution with a pH of 7.4. Intraluminal pressure was set at 60 mmHg and arteries were 
allowed to equilibrate for 30 minutes as described previously [19]. Measurements were 
initiated by adding a single dose of phenylephrine (PE, 10
-6
 mol/L) to the vessel chamber to 
check contractile smooth muscle viability in both endothelium-intact or denuded vessels. 
Hence, the endothelium was removed by back and forth rubbing the vessel lumen with a 
hair. Successful removal of the endothelium was confirmed by the absence of a dilative 
response to subsequent addition of acetylcholine (ACh; 3*10
-5
 mol/L). 
Intraluminal myogenic constriction was studied by obtaining active pressure-diameter 
curves over a pressure range of 60-140 mmHg in steps of 40 mmHg. Each pressure step 
was maintained for 3 minutes to reach a stable response. Subsequently the pressure was set 
back to 60 mmHg and the vessel segments were incubated with 1*10
-5
 mol/L S1P for 20 
min after which the active pressure-diameter curve was obtained again. Finally, to obtain 
the passive pressure-diameter curves, S1P and calcium containing Krebs solution was 
washed out and replaced by calcium-free Krebs solution supplemented with ethyleneglycol-
bis-(b-aminoethylether) tetra acetic acid (EGTA, 2 mmol/L), and the pressure-step 
measurements repeated. 
To also obtain vascular reactivity to PE, ACh and SNP, additional arteries of the 
aforementioned mesenteric were isolated, and the endothelium kept intact or removed (i.e. 
as in the above) before relaxation responses were assessed. For that matter, vessels were 
first pre-constricted with 3*10
-7
 mol/L PE. Subsequently, endothelium-dependent dilation 




 mol/L) were assessed in the intact vessels and endothelium-




 mol/L) in the denuded vessels. The  latter  
measurements were all performed at 60 mmHg. 
 
In order to measure the acute effects of FTY720 on contraction mediated by S1P receptors, 
additional mesenteric arteries of control rats were cut into vascular rings (1-2 mm in width). 
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Arterial rings were mounted on a small wire in individual bath chambers and equilibrated 
for 30 min in Krebs bicarbonate solution bubbled with 95% O2 and 5% CO2 at 37°C. Then, 
the calculated length of the vessel at 100 mmHg was determined by stepwise increasing the 
distance between two stainless steel wires in steps of 10 mm until the calculated transmural 
pressure exceeded 120 mmHg [20]. Vessels were held at each length for 1 min and the 
generated force and internal circumference were used to calculate the wall tension. The 
internal circumference and corresponding wall tension for each point could thus be fitted on 
an exponential curve for determination of L100 (i.e. calculated length of the vessel at 100 
mmHg). Arteries were allowed to equilibrate for 30 min in a standard Krebs solution at an 




 mol/L) -induced contraction was 
studied. Hence, contractions to S1P were studied both in the absence and presence of 
FTY720 (10
-5
 mol/L)  and/or indomethacin (10
-5 
mol/L as to block the involvement of 
cyclooxygenase (COX-)derived prostaglandins). 
 
Cell culture 
HUVECs were obtained from the Endothelial Cell Facility of the University Medical 
Center Groningen/University of Groningen and grown to confluence in six-well plates and 
treated with FTY720 (10
-7
mol/L) or vehicle for 24 hours before being washed once with 0.5 
ml PBS. Subsequently, S1P receptor protein levels were analyzed by Western blotting. For 
the Western blot analysis, cells were homogenized in radio-immunoprecipitation assay 
buffer, and protein concentration was determined according to the DC protein assay 
(Biorad, Veenendaal, Netherlands) using bovine albumin as a standard. Denatured protein 
(20 μg) was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) using 4%–20% precise protein gels (Pierce, Rockford, IL, USA), transferred to 
nitrocellulose membranes and incubated with primary antibodies against S1P1 (EDG-1 
ab11424 Abcam, Cambridge, UK) and S1P2 (EDG-5 Antibody (H-64), Santa Cruz, 
Heidelberg, Germany). Horseradish peroxidase-conjugated anti-rabbit immunoglobulin G 
(IgG, Santa Cruz, Heidelberg, Germany), Heerhugowaard, Netherlands) was used as 
secondary antibody. Signals were detected by the West Pico Chemiluminescent Substrate 
method (Life technologies, Bleiswijk, Netherlands) and quantified by densitometry. 
 




















Chemicals and compounds 
Vascular studies were performed using daily-prepared Krebs bicarbonate solution with the 
following composition NaCl, 120.4; KCl, 5.9; CaCl2, 2.5; MgCl2, 1.2; NaH2PO4, 1.2; 
glucose, 11.5; NaHCO3, 25.0) in (mmol/L).  S1P was purchased from Sigma Aldrich 
(Netherlands). FTY720 was generously provided by Novartis and was dissolved in demi 
water. Other chemicals and compounds were purchased from Merck (Merck, The 
Netherlands).  
 
Data analysis and calculations 
Data are expressed as mean ± SEM; n indicates the number of the rats or the number of 
investigated arteries. To characterize myogenic response, the following parameters were 
calculated from the pressure-diameter curve of each individual artery. Myogenic tone, 
describing myogenic behavior of an artery at a given pressure, was expressed as percent 
decrease in active diameter from the maximally dilated (passive) diameter determined at the 
same pressure in calcium-free/EGTA solution, i.e., myogenic constriction (%) = 100 [(DCa-
free – DCa)/DCa-free], where D is the diameter in calcium free (DCa-free) or calcium-containing 
(DCa) Krebs. The Area Under the Curve (AUC) for myogenic constriction (MC) were 
calculated from pressure curves and expressed as arbitrary units (AUs) using graph pad 
prism(5.0) Statistical differences were determined by t-test using SPSS. Differences were 
considered significant at p<0.05 (two-tailed).  
 
Results 
Body weight and hemodynamic effects of FTY720 treatment 
Animal body weight and hemodynamics are presented in Table 1. Body weights were 
similar in control treated and FTY720 treated animals. FTY720 treatment significantly 
reduced heart rate, although no effects of FTY720 were observed on blood pressure after 








Table 1. Animal body weight and hemodynamic effects of FTY720.  
 Control (n = 6) FTY720 (n = 6) 
Body Weight (g) 472±12 449±13 
Heart Rate (bpm) 408±7 361±7 * 
Systolic Blood Pressure (mmHg) 137±7 135±7 
Diastolic Blood Pressure(mmHg) 83±7 83 ±4 
Data are expressed as mean ± SEM, * p<0.01 vs control.  
 
Long term of FTY720 treatment effects on mesenteric artery reactivty  
To investigate the effects of long term FTY720 treatment on the microvasculature, we 
examined vascular myogenic function and response to S1P of isolated mesenteric arteries in 
a perfusion setup. To determine the role of the endothelium in vascular function, 
measurements were performed in intact and denuded blood vessels and presented as a 
pressure range of 60-140 mmHg and calculated as area under the curve (AUC) respectively 
(figure 1A, 1B). 





















Figure 1. Responses of endothelium-intact and -denuded mesenteric arteries of rats chronically treated with 
or without FTY720. (A) Pressure induced myogenic constriction. (B) Area under the curve of pressure induced 
myogenic constriction. (C) S1P induced constriction. (D) Area under the curve of S1P induced constriction. Data 
are expressed as mean ± SEM.  * p<0.05 vs control.   
 
Next, myogenic constriction of mesenteric vessels was assessed after pretreatment with S1P 
(10 µM). Addition of S1P to mesenteric arteries resulted in a strong constriction at 60 
mmHg in both intact and denuded control and FTY720 treated animals (figure 1C). 
Subsequent increases in intraluminal pressure resulted in an increase of myogenic 
constriction in vessels from control and intact vessels from FTY720 treated animals. In 
contrast, in FTY720 treated animals addition of S1P to endothelium denuded vessels did 
not result in an increase of myogenic constriction (figures 1C and 1D). As a result no 
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differences were observed in constriction in endothelium-intact vessels compared with 
endothelium-denuded vessels of untreated animals. Iin FTY720 treated animals, however, 
responses to S1P were completely blocked in denuded arteries. The latter suggests that the 
endothelium is essential for maintaining S1P mediated constriction after long term 
treatment with FTY720. 
 
Moreover, the treatment effects of FTY720 appear specific for S1P-mediated responses 
since contraction to PE was not significantly different between treated and untreated 
animals, neither in endothelium-intact nor in endothelium-denuded artery segments (figure 
2A; response to PE: intact 46±6%, FTY720 intact 60±8%, denuded 70 ±10%, FTY720 
denuded 48±9 % of KCl). Also, the similar responses to ACh and SNP in arteries of 
untreated and FTY720 treated animals (figure 2B and 2C) further rules out that the above 
described differences in the response to S1P were due to some general (d-)effect of 
FTY720 treatment on endothelial and/or vascular smooth muscle cell function. 
 





















Figure 2 Vascular reactivity of endothelium-intact and -denuded mesenteric arteries of rats chronically 
treated with or without FTY720. (A) Contraction-response curve to phenylephrine (PE). (B) Relaxation-
response curves to acetylcholine (Ach). (C) Relaxation-response to sodium nitroprusside (SNP) in endothelium 
denuded arteries. Data are presented as mean±SEM. 
 
Acute effects of FTY720 treatment on mesenteric artery contraction 
To further investigate how FTY720 treatment may have affected S1P mediated contraction 
of endothelium intact mesenteric arteries, we also  studied the acute effects of FTY720 on 
S1P induced contractions in isolated mesenteric artery ring preparations. Incubation with 
FTY720 caused a significant leftward shift of the dose-response curve to S1P (figure 3, 
Table 2). Addition of indomethacin, a nonselective inhibitor of cyclooxygenase (COX) 1 
and 2, partially reversed the effects of FTY720. These results suggest that FTY720 acutely 









































































































prostaglandins. Furthermore, it seems that this acute effect of FTY720 was specific for 
S1P-induced contraction since responses to KCl remained unaffacted in presence of 
FTY720 (data not shown).  
 
Table 2. Concentration-response parameters for S1P induced contractions of mesenteric arteries. 
 
Log EC50   Emax 
CON (n=6) - 6.30 ±0.10 36.2 ±4.6 
CON + INDO (n=6) - 6.27 ±0.06 34.0 ±4.5 
FTY720 (n=6) - 6.65 ±0.09* 43.7 ±4.7 
FTY720 + INDO (n=6) - 6.52 ±0.13 37.8 ±4.7 

































Figure 3. Acute effects of FTY720 on S1P mediated contraction. Pre-treatment with FTY720 caused a leftward 
shift of the CR curve to S1P; this could be in part reversed by addition of indomethacin (*p<0.05 EC50 FTY720 vs 
control). 





















Effect of FTY720 on endothelial S1P receptor subtype expression 
Since the presence of endothelium was essential for maintaining S1P mediated constriction 
after long term treatment with FTY720, we investigated the effects of FTY720 on the 
expression of S1P receptor subtypes in cultured human endothelial cells (HUVEC). 
FTY720 treatment significantly reduced S1P1 protein expression while S1P2 expression 
was unaffected (figure 4), indicating that FTY720 treatment shifts the relative expression of 
S1P receptors towards S1P2. 
 
 
Figure 4. Effect of FTY720 on the expression of S1P1 and S1P2 in cultured human endothelial cells 
(HUVEC). The expression of S1P1 was significantly reduced by FTY720. Data are presented as mean ± SEM. * p 






This is the first functional study to characterize the chronic effects of FTY720 treatment on 
contractile responses to S1P in small resistance arteries of Wistar rats. The main finding of 
this study is that the endothelium of mesenteric arteries of healthy animals is able to 
compensate for a complete loss of responsiveness of the smooth muscle layer to S1P after 
FTY720 treatment through a mechanism which enhances production of contractile 
prostaglandins by the endothelium.  
 
Chronic treatment of FTY720 leads to bradycardia without reduction of blood pressure in 
Wistar rats. This balance in maintenance of blood pressure indicates the compensatory 
mechanism of vascular system to adjust the blood pressure tone, however in the current 
study various vascular function such as vascular tone and vascular response to PE remained 
unchanged in control mesenteric arteries compare with FTY720. This finding is partially 
concordant with previously findings of Spijkers et al., who found FTY720 not to affect 
vascular contraction, per se, in non-hypertensive rats [21].  
 
In this study, our findings are in line with several previous studies demonstrating that 
FTY720 causes sustained internalization and degradation of S1P receptors [22]. Addition of 
S1P did not affect the vascular contraction of intact vessels in chronically treated animals 
compared with control. In contrast, in denuded arteries, long term FTY720 treatment 
caused a complete inhibition of S1P mediated constrictions, indicating that the smooth 
muscle layer of FTY720 treated animals had completely lost responsiveness to S1P. As 
smooth muscle cells are known to express S1P1 and S1P3, our findings most likely reflect 
the functional consequences of down-regulation of these receptor subtypes in the smooth 
muscle layer of FTY720 treated animals. Moreover, our findings indicate that the 
endothelium compensates for the loss of S1P signaling of the smooth muscle layer, as S1P 
responsiveness was maintained in intact vessels of FTY720 treated animals. As S1P 
mediated augmentation of myogenic constriction arteries was completely absent in denuded 
mesenteric, it is unlikely that the endothelium of intact arteries compensates through 
impaired productions of relaxing factors. Indeed, relaxation responses to acetylcholine of 
mesenteric arteries did not differ between vehicle and FTY720 treated animals. Rather, the 
endothelium most likely produces endothelium-derived contractile factors (EDCFs), which 
maintained S1P mediated constrictions in intact mesenteric arteries of FTY720 treated 




















animals. A well-known source of EDCFs consists of cyclooxygenase (COX)-derived 
contractile prostaglandins. 
 
Our findings are in line with those of Spijkers et al., who reported correlation between S1P 
and hypertension in spontaneous hypertensive rats (SHR) [23]. Previously, a link between 
FTY720 and endothelial COX has been described in a study showing that FTY720 caused 
contractions of isolated carotid arteries of spontaneous hypertensive rats (SHR), which 
could be blocked by denudation, indomethacin and thromboxane synthase inhibitors [21].  
However in mast cells, FTY720 inhibits prostaglandin and thromboxane secretion 
independently of S1P receptors [24]. Our findings on mesenteric arteries elucidate that S1P 
mediated contractions after FTY720 treatment augments the COX secretion in endothelial 
cells and enhances sensitivity to S1P; as reflected by a significantly lower log EC50 value. 
It is known that in smooth muscle cells S1P can regulate COX activities via protein kinase 
B and mitogen-activated protein kinases pathways [25]. In addition, our data shows that 
inhibiting COX partly reversed the effects of FTY720, indicating that the effects of 
FTY720 were at least in part mediated through COX-derived PGs in endothelium. Taken 
together, our results and previous studies suggest that the endothelium may enhance 
vascular contraction in FTY720 treated animals by stimulating endothelial COX mediated 
contractile prostaglandin production. 
 
Relative expression of S1P1 and S1P2 after FTY720 treatment caused a shift of S1P 
receptors towards S1P2. Although coupling of S1P2 to COX has not yet been demonstrated 
in aortic vascular endothelial cells, stimulation of S1P2 of endothelial cells from mouse 
retina enhanced COX expression [26]. Furthermore, S1P induced COX-2 expression and 
PGE2 formation through S1P2 in renal mesangial cells [27]. Therefore, the enhanced 
endothelium mediated contraction in FTY720 treated animals may be caused through 
enhanced contractile prostaglandin production caused by a shift in the relative expression of 
S1P1 and S1P2. 
 
In conclusion, to the best of our knowledge, this is the first study to demonstrate that the 
endothelium of mesenteric arteries of healthy animals may be able to compensate for the 
complete loss of responsiveness of the smooth muscle layer to S1P after long term FTY720 
treatment through a mechanism that involves enhanced production of contractile 
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prostaglandins by the endothelium. Although this mechanism did not cause changes in 
blood pressure in healthy animals, it may contribute to the development of hypertension in 
conditions in which the COX system is already activated, such as in spontaneous 
hypertensive rats (SHR). 
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Summary and General Discussion 
 
The world is currently witnessing an alarming increase in metabolic syndrome (MS) and 
diabetes, with an associated increase in morbidity, mortality and health care burden for the 
society. Type 2 diabetes mellitus (T2DM) accounts for approximately 90% of all diabetes 
cases and is associated with insulin resistance, which originates mainly from the increased 
prevalence of obesity resulting from a combination of lifestyle and genetic susceptibility[1]. 
Diabetes is associated with a spectrum of several disorders, including vasculopathy and end 
organ damage. To control and treat diabetes and its associated risks, proper tools and 
therapeutics are necessary. Preferably, such strategies should be based on the knowledge 
how to predict, prevent and properly treat the subjects or patients at risk. 
In chapter 2 of this thesis, we aimed to determine “who is at risk” by assessing the 
“predictability” of the end organ damage in the Zucker Diabetic Fat (ZDF) rat model of MS 
and T2DM development. Despite a similar blood glucose level, progression of renal 
damage in these diabetic rats varies among individuals. We showed that vascular properties 
of intra-renal vessels of ZDF uninephrectomized rats as assessed before development of 
overt diabetes predicts the future development of kidney injury in late diabetes. In this 
chapter, we demonstrated that both myogenic tone and endothelial function of still healthy 
individuals predict their progression towards kidney injury during diabetes development. 
In chapter 3 we examined the impact of diabetes on end organ damage in a less well-
studied organ in ZDF diabetic rats: the brain. In particular, we found the diabetic state to 
induce features of neurodegenerative damage such as in Alzheimer’s (AD) disease. Our 
findings indicated that ZDF diabetic rats, similarly to AD, show disturbed protein 
homeostasis originating from an increase in protein aggregation formation along with the 
attenuation of protein clearance mechanisms, such as autophagy. Moreover, increased 
oxidative stress is present in the diabetic brain, which probably initiates a further 
development and progression of neurodegenerative damage[2]. Because of the involvement 
of oxidative stress in brain damage, H2S, as a potent antioxidant agent[3], is suggested to 
play a prominent role in defense against protein aggregation. Cystathionine-β-synthase 
(CBS) represents one of the main enzymes responsible for H2S production, which can 
inhibit the deleterious products formation such as advanced glycation end-products[4] [5]. 
First, we found a marked decreased expression of CBS in the brain of ZDF rats. Moreover, 


















exogenous H2S not only protected brain slices of diabetic ZDF from oxidative stress 
damage and protein aggregation, but also those from normal rats when provoked with 
medium containing a high glucose concentration. These beneficial effects of H2S can be 
brought about either by its anti-oxidant effect or by the inhibition of protein synthesis via 
the mTOR pathway [3][6]. Overall, our results suggest that the reduction in CBS 
expression contributes to the increased protein aggregation in ZDF animals. Consequently, 
maintaining or boosting brain H2S production may represent a novel therapeutic approach 
to alleviate brain damage in diabetes. 
Many therapeutics applied in T2DM are principally intended to optimize blood glucose 
level, either by increasing sensitivity of cells to glucose or by reducing glucose production. 
However, such therapies may also have additional impacts on the cardiovascular system 
even beyond hyperglycemic control. In chapter 4, we explored such ‘off-target’ properties 
of currently used drugs, i.e. metformin and vildagliptin. Particularly, we considered the 
control of high blood pressure to improve vascular function, representing an equally 
important measure in T2DM to reduce morbidity[7]. To this end, we assessed the 
pleiotropic effects of metformin and vildagliptin on vascular function in spontaneously 
hypertensive rats (SHR) with STZ-induced type 1 diabetes, a model in which the drugs do 
not influence glycemic control. Indeed, SHR rats showed both hypertension and endothelial 
dysfunction, i.e. two factors classically preceding the development of CVD[8]. We found 
that both hypertension and impaired endothelium-dependent relaxation (EDR) were 
counteracted by chronic metformin treatment, via an increase in aortic contractile 
prostaglandins (PGs) on the one hand but an even stronger increase in dilative NO and 
EDHF on the other hand. In particular, the metformin induced increase in EDHF 
production in (STZ)-SHR rats as compared to the rise in contractile PGs seems to signify 
that increased EDHF production was the most responsible for overall improvement of 
EDR. Similarly to metformin, vildagliptin also reduced blood pressure and restored 
endothelial function in SHR, mainly via the inhibition of COX-derived contractile PGs and 
increasing EDHF production. In contrast however, vildagliptin did not improve EDR in the 
diabetic SHR, which indicates that the pathophysiologic condition of hyperglycemia is also 
an important player in the modulation of the vildagliptin effect on aortic endothelial 
function. Interestingly, H2S has recently been proposed as a potential EDHF. We showed 
that up-regulation of H2S correlates with EDHF and with the decrease in systolic blood 
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pressure, which suggests that it may contribute to the antihypertensive effect of metformin 
and vildagliptin. Together, our results in chapter 4 imply that pleiotropic effects of both 
metformin and vildagliptin improve vascular endothelial function in diabetes.  
To really comprehend vascular dysfunction in diabetes we need to better understand its 
underlying mechanisms. Sphingosine-1-phosphate (S1P) and its receptors are involved in 
the series of reactions, which are significantly capable of modulating vascular function. 
However, the role of S1P in the physiological condition is not yet well understood. The 
function of S1P and its receptors in various vascular layers are responsible for its ultimate 
effect on vascular function [9]. Any dysregulation among these receptors may lead to 
cardiovascular dysfunction such as the impairment of vasomotor regulation and 
hypertension[9]. To address this, we investigated in chapter 5 the function of S1P and its 
receptors in the non-diabetic condition by exploring the effect of chronic FTY720 treatment 
on endothelial function and myogenic tone. FTY720 is considered as an S1P receptor 
agonist, which is clinically applied for the treatment of multiple sclerosis (Fingolimod) [10] 
[11]. Our findings revealed that chronic treatment with FTY720 has a dual action on 
vascular function of mesenteric arteries. On the one hand FTY720 reduces the sensitivity of 
the mesenteric smooth muscle cells (SMC) to stretch-induced constriction, which in turn 
leads to a reduction of the vascular response to S1P. On the other hand, by increasing 
endothelial production of COX-derived contractile PGs, FTY720 compensates for 
contraction loss of the SMC to S1P and maintains the contractile properties of the vessel 
[12]. Finally, our findings show that the augmentation in vascular tone following to 
FTY720 treatment can be attributed to the increasing of the COX derived compounds 
which may get regulated by S1P2 receptors, and reduced S1P1 receptor expression. 
 
Conclusion and future perspective: 
In conclusion, T2DM is a progressive disease which finally leads to irreversible end organ 
damage. By identifying the functional properties of the kidney’s microvasculature during 
the premature diabetic condition, this thesis for the first time highlights the physiologic 
variation in vascular function as an early predictor of renal damage and chronic kidney 
disease (CKD) in diabetes. Firstly therefore, our findings may be helpful to identify T2DM 
patients with a high risk of diabetic nephropathy. Secondly, we showed that metformin and 
vildagliptin, being classic anti-diabetic drugs, also exert promising pleiotropic effects that 


















could be of value to improve CVD outcomes in diabetes. Particularly, our findings may 
help us to better understand the vascular mechanisms by which metformin and vildagliptin 
exert their anti-hypertensive action. In this respect, our studies suggest H2S to be a 
protective mediator in diabetes. Acting as a potential EDHF in vasomotor regulation 
[13,14], H2S may help to improve endothelial dysfunction and render additional 
pharmacotherapeutic rationales to reduce vascular complications in diabetes. In addition, 
H2S may act as an anti-oxidative agent which inhibits brain damage in diabetes. The 
cumulative beneficial effects of H2S make it a promising candidate to be explored in 
therapeutic strategies.  
Collectively, our findings provide innovative ways to improve organ preserving strategies 
in diabetes, theoretically by measuring of renal vascular function as a new approach to 
identify individuals at risk for nephropathy, by demonstrating the additional benefit of 
existing anti-diabetic drugs and by identifying novel drug targets including the H2S system 
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De wereld is momenteel getuige van een sterke toename van het aantal patiënten met 
diabetes en de hiermee samenhangende toename in ziekte- en sterftecijfers, evenals impact 
daarvan op de gezondheidszorg en maatschappij. Circa 90% van alle diabetes patiënten 
bestaat uit type 2 diabetes mellitus (T2DM) waarbij er sprake is van een verminderde 
gevoeligheid van lichaamscellen voor de werking van insuline (insulineresistentie). Als 
gevolg hiervan blijft er te veel bloedsuiker ongebruikt in het bloed zitten en deze verhoogde 
suikerspiegel is op langere duur ongezond, in eerste instantie vooral voor bloedvaten. De 
huidige toename in T2DM wordt gerelateerd aan het meer voorkomen van overgewicht en 
obesitas als gevolg van een combinatie van hedendaagse levensstijl en genetische aanleg 
[1]. Overgewicht is onderdeel van het metabool syndroom (MS), een aandoening waarbij 
een aantal stofwisselingsparameters - gewicht/buikomvang, bloeddruk, en bloedspiegels 
van cholesterol, triglyceriden en glucose - in combinatie verhoogd aanwezig zijn. MS wordt 
ook wel gezien als een voorloper van T2DM. 
Diabetes is geassocieerd met een aantal stoornissen die leiden tot functionele en structurele 
afwijkingen aan grote en kleine bloedvaten. Bovendien treedt er schade op aan de weefsels 
en organen die door deze bloedvaten worden voorzien van zuurstof en nutriënten (b.v. hart, 
nier, brein, oog en extremiteiten). De meeste diabetes patiënten overlijden uiteindelijk niet 
aan diabetes zelf maar aan de bijkomende gevolgen, en dan met name hart- en vaatziekten; 
de huidige mondiale ontwikkeling wijst dus op een zorgwekkende toename daarvan. Om 
diabetes en de ontwikkeling van eindorgaanschade als gevolg daarvan te kunnen 
behandelen en controleren zijn nieuwe en innovatieve therapieën nodig. Strategieën om 
deze te ontwikkelen zouden bij voorkeur gebaseerd moeten zijn op kennis om individuen 
die een verhoogd risico lopen op eind-orgaanschade in diabetes vroegtijdig te identificeren 
teneinde deze patiënten gericht te behandelen. Gezien het belang van intacte bloedvaten 
voor behoud van orgaanfunctie en het voorkomen van schade hebben we in dit proefschrift 
in het bijzonder de rol van vaatfunctie en endotheelfunctie
1
  in diabetes en het effect van 
                                                 
1   Het endotheel is een cellaag welke de binnenbekleding van de bloedvaten vormt en werkzaam is 
als een "regulator" van allerlei belangrijke processen betrokken bij vaatfunctie (doorlaatbaarheid, 
vernauwing/verwijding, bloedstolling, vorming van nieuwe bloedvaten). Het endotheel produceert 
daartoe tal van stoffen die bij een of meerdere van deze processen betrokken is. Een "verslechterde" 
werking van deze cellaag (endotheel disfunctie) wordt gezien als een eerste stap bij de ontwikkeling 
hart- en vaatziekten. Het meten van endotheelfunctie is dus het bepalen van een parameter (e.g. 

















therapieën hierop willen bestuderen. 
Eerst hebben de vraag "wie loopt verhoogd risico" getracht te beantwoorden door de 
voorspelbaarheid van eindorgaanschade in diabetes  te bestuderen in de Zucker Diabetic 
Fatty (ZDF) rat. Dit is een rattenmodel van MS en T2DM met ontwikkeling van 
eindorgaanschade in de vorm van nierschade. Deze nierschade uit zich als eiwitverlies in de 
urine (proteïnurie) hetgeen relatief eenvoudig te volgen is in de tijd. Tijdens eerdere studies 
was al naar voren gekomen dat de vaatfunctie bij een groep normaal gezonde (jonge) ratten 
onderling sterk variabel is, en dat een betere endotheelfunctie in kleine nierarteriën 
voorspelde dat deze individuen later minder nierschade ontwikkelden wanneer ze werden 
onderworpen aan 5/6 nefrectomie (i.e. een experimentele manier om nierschade op te 
wekken zonder dat daarbij bloedglucose waarden stijgen en diabetes optreedt). 
Hier hebben we dit experiment willen herhalen maar nu met ZDF ratten, die op termijn 
T2DM en ook nierschade als gevolg daarvan zouden gaan ontwikkelen. In hoofdstuk 2 
werd bij een groep jonge ZDF ratten de endotheelfunctie in kleine nierarteriën bemeten op 
een leeftijd dat ze weliswaar zwaarlijvig waren maar nog niet diabeet (i.e. pre-diabeet), wat 
weerspiegeld wordt in de  normale bloedglucose waarden en afwezigheid van nierschade. 
Deze dieren werden daarna vervolgd voor de ontwikkeling van diabetes waarbij de 
bloedglucose waarden sterk opliepen, evenals de proteïnurie (als maat voor nierschade). 
Aan het eind van de studie bleek dat individuen met een betere endotheelfunctie tijdens hun 
pre-diabetes fase later een geringere mate van proteïnurie toename ontwikkelden terwijl ze 
diabeet werden. M.a.w. de vaatfunctie in de nier is aanzienlijk variabel tussen vergelijkbare 
individuen die op dat moment (nog) geen T2DM hebben. Toch is deze "normale" variatie in 
vaatfunctie in de nier een vroege voorspeller voor de ernst van latere nierschade tijdens 
T2DM ontwikkeling bij deze individuen. De resultaten impliceren dat er dus opties zijn om 
individuen met een verhoogd risico op ernstige nierschade ontwikkeling tijdens diabetes al 
vroegtijdig te identificeren. 
 
Behalve nierschade is diabetes ook geassocieerd met ontwikkeling van schade aan het 
brein. Wederom gebruik makend van ZDF ratten in hoofdstuk 3 vonden we kenmerken van 
neurodegeneratieve schade ontwikkeling (beschadiging aan zenuwcellen) zoals die ook bij 
de ziekte van Alzheimer voorkomen (waarin dit gepaard gaat met verlies van cognitieve 
functies). Net als bij Alzheimer vertoonden ZDF ratten een toegenomen samenklontering 
(aggregatie) van eiwitten in het brein waardoor deze niet meer goed functioneerden. 
Bovendien was er sprake van toegenomen oxidatieve stress (meer vrije zuurstof radicalen) 
in het diabetes brein; deze draagt waarschijnlijk bij aan de ontwikkeling en voortschrijding 
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van die neurodegeneratieve schade [2]. 
Vanwege de vermeende betrokkenheid van verhoogde oxidatieve stress bij hersenenschade 
wordt gedacht dat anti-oxidanten - zoals bijvoorbeeld het vrij recent ontdekte H2S - een 
prominente rol zouden kunnen spelen bij het tegengaan van de vorming van 
eiwitaggregaten. In het brein is cystathionine- β-synthase (CBS) een van de belangrijkste 
enzymen die de productie van H2S medieert [4,5]. Ten eerste vonden we een sterk 
verlaagde expressie van CBS in hersenen van diabete ZDF ratten, hetgeen een bijdragende 
verklaring zou kunnen zijn voor de verhoogde oxidatieve stress aldaar. Ten tweede vonden 
we dat oxidatieve stress en eiwitaggregatie in ZDF hersencoupes ("levend" gehouden in een 
kweekmedium) kon worden verminderd wanneer wij daar zelf NaHS aan toevoegden; 
NaHS is een donor waaruit de anti-oxidant H2S vrijkomt. Hetzelfde resultaat werd 
verkregen wanneer wij NaHS gaven aan controle hersencoupes (afkomstig van niet-
diabetes ratten) die waren overgebracht in een kweekmedium met een hoge concentratie 
glucose (om zo diabetes condities te simuleren). Verder denken we dat behalve via anti-
oxidante effecten ook een effect op het mTOR systeem (een systeem dat de eiwitsynthese 
stimuleert) een rol zou kunnen hebben gespeeld in de gunstige effecten van H2S. 
Behandeling van diabetes hersencoupes in een kweekmedium met toegevoegd NaHS 
onderdrukte namelijk ook de toegenomen expressie en activering van mTOR aldaar. Gezien 
deze resultaten denken wij dat het behouden of stimuleren van H2S productie in de brein 
een belangrijk doelwit zou kunnen zijn voor de ontwikkeling van nieuwe therapie(en) om 
hersenschade in diabetes te beperken. 
 
Veel van de in T2DM gebruikte therapieën richten zich primair op het verbeteren van de 
bloedglucose waarden, ofwel door de gevoeligheid van lichaamscellen voor glucose te 
verhogen of door de glucoseproductie in het lichaam te verlagen. Dergelijke therapieën 
kunnen echter ook effecten hebben die verder gaan dan het controleren van te hoge 
bloedglucose waarden, of zelfs onafhankelijk daarvan optreden. Met name interessant in dit 
opzicht vonden wij het eventuele (neven-)effect van dergelijke therapieën op vaatfunctie, 
o.a. gezien het belang van een intacte vaatfunctie ter voorkoming van orgaanschade en 
behoud van orgaanfunctie (zie eerder). In hoofdstuk 4 hebben we dergelijke "off-target" 
effecten willen verkennen van 2 geneesmiddelen die momenteel algemeen worden gebruikt 
bij de behandeling van T2DM, te weten metformine en vildagliptine. Daarbij hebben we 
voor ogen gehouden dat, net als controle van te hoge bloedglucose waarden, ook de 
controle van te hoge bloeddruk een even belangrijk doelwit is om morbiditeit in T2DM te 

















vaatfunctie zonder dat daarbij de bloedglucose waarden worden beïnvloed valt onder de 
zogenaamde "pleiotrope effecten" van beide geneesmiddelen: het optreden van gunstige 
andere effecten dan die waarvoor het geneesmiddel werd ontworpen. 
Om een pleiotrope werking van metformine en vildagliptine op de bloeddruk en vaatfunctie 
te bestuderen hebben we gebruik gemaakt van de zogenaamde spontaan hypertensieve 
ratten (SHR), een rattenstam met een erfelijk bepaalde hoge bloeddruk of hypertensie. Deze 
ratten werden eenmalig ingespoten met streptozotocin (STZ), een geneesmiddel dat in 
ratten specifiek toxisch is voor β-cellen in de pancreas. Deze cellen produceren normaliter 
de insuline die nodig is om de suikerspiegels in het bloed te reguleren, maar raken dus 
beschadigd na STZ-behandeling. Als gevolg van die beschadiging en het gebrek aan 
insulineproductie zullen de bloedglucose waarden stijgen waardoor deze ratten type 1 
diabetes mellitus (T1DM) ontwikkelen. In tegenstelling tot T2DM waarin sprake is van 
insulineresistentie (zie boven), is er bij T1DM dus sprake van een insulinegebrek; deze 
vorm wordt ook wel insuline-afhankelijke diabetes genoemd omdat T1DM-patiënten 
afhankelijk zijn van insuline-injecties voor verlaging van bloedsuiker spiegels. Voorts kan 
worden opgemerkt dat geneesmiddelen zoals metformine en vildagliptine - welke vooral 
worden gebruikt voor het tegengaan van insulineresistentie in T2DM - dus niet of ook veel 
minder effectief zullen zijn wat betreft bloedglucose verlaging in T1DM. Op die manier 
beschouwd is de STZ-SHR dus een ratmodel van T1DM met hypertensie waarin de 
eventuele behandelingseffecten van metformine en vildagliptine (op bloeddruk en 
vaatfunctie) onafhankelijk zijn van een beïnvloeding van de bloedsuiker spiegels. 
 
In de studie in hoofdstuk 4 werden ratten dus langdurig behandeld met vildagliptine of 
metformine, of bleven ter vergelijking onbehandeld. Deze behandelingen werden gegeven 
aan zowel hypertensieve ratten met T1DM (STZ-SHR) als hypertensieve ratten zónder 
T1DM (SHR). Als eerste konden we bevestigen dat SHR ratten inderdaad zowel 
hypertensie als endotheel disfunctie ontwikkelden (i.e. 2 factoren die klassiek 
voorafgaan/bijdragen aan de ontwikkeling van hart- en vaatziekten) [8]. Behandeling met 
metformine verlaagde de bloeddruk en verbeterde de endotheel-afhankelijke relaxatie 
(EDR), zowel in ratten zonder als met T1DM. In beide condities leek de verbeterde 
endotheelfunctie na metformine vooral te kunnen worden toegeschreven aan een verhoogde 
productie van NO en m.n. EDHF; dit zijn beide vaatverwijdende endotheelfactoren die 
bijdragen aan de totale EDR. Ook vildagliptine verlaagde de bloeddruk en verbeterde de 
totale EDR, in dit geval echter vooral door verhoogde productie van vaatverwijdende 
endotheel prostaglandines, maar alléén in ratten zonder T1DM. In ratten met T1DM trad dit 
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effect van vildagliptine niet op en was de EDR (ondanks verhoogde productie van EDHF) 
niet significant verbeterd en ook bloeddruk niet significant verlaagd. Dit suggereert dus dat 
het behandelingseffect van vildagliptine op endotheelfunctie in belangrijke mate werd 
beïnvloed door verhoogde bloedglucose waarden in T1DM, dit dus i.t.t. metformine! 
Opmerkelijk in deze studie was verder dat metformine en vildagliptine beide de plasma 
concentratie van H2S significant verhoogde, zowel in ratten zonder als met T1DM. Zoals 
eerder gesteld: H2S staat de laatste tijd sterk in de belangstelling vanwege z’n vermeende 
beschermende effect tegen eind-orgaanschade (zie ook hoofdstuk 3). Tevens wordt H2S 
naar voren geschoven als een mogelijke kandidaat voor EDHF. De toename van H2S in 
onze studie correleerde met een toename van EDHF, evenals met een afname in bloeddruk. 
Dit suggereert dat H2S een bijdragende rol zou kunnen hebben gehad in de anti-
hypertensieve effecten van metformine and vildagliptine. Al bij al suggereren de resultaten 
in hoofdstuk 4 dat een verbetering van de vasculaire endotheelfunctie behoort tot de 
pleiotrope effecten van metformine in diabetes. 
 
Om vaatdisfunctie in diabetes nog beter te kunnen behandelen is er een voortdurende 
behoefte naar meer en dieper begrip van relatief nieuwe en nog onbekende mechanismen in 
vaatfunctie. Interessant in dit opzicht is de mogelijke rol van het sphingosine-1-phosphaat 
(S1P) systeem en het geneesmiddel fingolimod, ook wel FTY720 geheten. Fingolimod 
beïnvloedt de activiteit van het immuunsysteem en wordt klinisch toegepast bij de 
behandeling van multiple sclerose, een ziekte waarbij heeft het immuunsysteem een 
ontstekingsreactie opwekt gericht tegen het centrale zenuwstelsel. De actieve metaboliet 
van fingolimod is het fingolimodfosfaat; deze bindt zich aan S1P-receptortype-1 dat 
aanwezig is op de lymfocyten (ontstekingscellen in het bloed). Het passeert op deze manier 
gemakkelijk de bloed-hersenbarrière om zich daarna te binden aan de S1P-receptortype-1 
op de zenuwcellen in het centraal zenuwstelsel. Als functionele antagonist ("tegenhanger") 
van de S1P-receptortype-1 op de lymfocyten, zorgt fingolimodfosfaat er ook voor dat 
lymfocyten niet meer weg kunnen komen uit de lymfeknopen, wat een herverdeling van 
lymfocyten in organen/lichaam veroorzaakt. Deze herverdeling vermindert de infiltratie van 
ontstekingsopwekkende lymfocyten in het centrale zenuwstelsel en daarmee hun 
betrokkenheid bij beschadiging van zenuwweefsel in multiple sclerose, zo is de 
veronderstelling. 
S1P-receptoren zijn echter óók aanwezig in de vaatwand, zowel in endotheelcellen als in 
gladde spiercellen. Bovendien lijkt het er op dat ze betrokken zijn bij een reeks van reacties 

















begrip van de rol van het S1P-systeem in vaatfunctie hebben we nog niet, laat staan dat we 
weten of het een mogelijk relevant systeem zou kunnen zijn om te beïnvloeden ten gunste 
van het behoud van vaatfunctie in diabetes. In hoofdstuk 5 hebben we dit verder willen 
verkennen door het behandelingseffect van fingolimod op vaatfunctie in niet-diabetes 
omstandigheden te onderzoeken. Hiertoe werd een groep normaal gezonde ratten gedurende 
6 weken behandeld met fingolimod alvorens te worden bestudeerd op vaatfunctie van 
kleine mesenteriaal arteriën. In de bloedvatpreparaten van onbehandelde ratten resulteerde 
toediening van S1P in een concentratie-afhankelijke vaatvernauwing, zowel in preparaten 
mét intact endotheel als in preparaten waarbij het endotheel eerst kunstmatig was 
verwijderd. Echter, na behandeling met fingolimod was de S1P-vernauwings respons 
vrijwel geheel afwezig, ten minste in de preparaten zónder het endotheel; in de preparaten 
met intact endotheel was de S1P-vernauwigs respons wel min of meer normaal. 
Wij interpreteren dit als een tweeledig effect van fingolimod op de vaatfunctie. Enerzijds 
neemt de S1P-responsiviteit van gladde spiercellen in de vaatwand sterk af na fingolimod, 
mogelijk als gevolg van een verminderd aantal S1P-receptortype-1 aldaar: dit zagen we 
namelijk ook gebeuren bij endotheelcellen wanneer deze werden gekweekt met fingolimod 
aanwezig in het kweekmedium. Anderzijds lijkt het endotheel in staat te compenseren voor 
de verminderde S1P-responsiviteit van gladde spiercellen door zelf meer vaatvernauwende 
factoren (zogenaamde contractiele prostglandines) vrij te maken waarop de gladde 
spiercellen nog wel goed reageren. Het zou goed kunnen zijn dat de productie van dergelijk 
contractiele endotheelfactoren gekoppeld is aan een werking van S1P op S1P-receptortype-
2 want i.t.t. S1P-receptortype-1 waren S1P-receptortype-2 niet verminderd in gekweekte 
endotheelcellen in aanwezigheid van fingolimod. 
In voorafgaande studies hadden we al gevonden dat voorbehandeling met fingolimod bij 
zogenaamde cardiopulmonaire bypass operaties een gunstige werking heeft wat betreft het 
behoud van vaatfunctie. De resultaten in hoofdstuk 5 geven ons nu meer detail inzicht in de 
mogelijke werkingsmechanismen van fingolimod en het S1P-systeem in vaatfunctie 
waarbij het adaptieve en interactieve karakter van het endotheelfunctie jegens gladde 
spiercelfunctie opvallend is. Het is echter ook duidelijk dat vervolgstudies onontbeerlijk 
zijn teneinde beïnvloeding van het S1P-systeem middels fingolimod als potentiële 




Diabetes is een progressieve ziekte die uiteindelijk leidt tot onherstelbare orgaanschade. 
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Gezien het belang van intacte bloedvaten voor behoud van orgaanfunctie en voorkoming 
van orgaanschade hebben we in dit proefschrift in het bijzonder de rol van vaatfunctie in 
diabetes bestudeerd en het effect van therapieën hierop. Als eerste hebben we kunnen 
vaststellen dat de functie van kleine bloedvaten in de nier reeds in het voorstadium van 
diabetes aanzienlijk variabel is tussen ogenschijnlijk vergelijkbare individuen, en dat deze 
"normale" variatie een vroege voorspeller is voor de ernst van latere nierschade tijdens 
diabetes. Daarmee mogen onze bevindingen dus principieel behulpzaam zijn bij het 
identificeren van diabetes patiënten met een verhoog risico op diabetische nefropathie 
(verlies van nierfunctie door diabetes). 
Als tweede hebben we laten zien dat metformine and vildagliptine als klassieke diabetes 
medicijnen ook veelbelovende (pleiotrope) neveneffecten hebben - die onafhankelijk van  
bloedglucose beïnvloeding optreden - die van waarde kunnen zijn bij het tegengaan van 
hart- en vaatziekten in diabetes. Onze bevindingen geven in het bijzonder meer inzicht in 
vaatfunctie mechanismen via welke metformine en vildagliptine hun bloeddrukverlagende 
effecten bewerkstelligen. De in het oog springende resultaten hierbij accentueren een 
beschermende werking van H2S in diabetes. Als potentiële endotheelfactor lijkt H2S bij te 
dragen aan het verbeteren van de vaatfunctie na behandeling met metformine en 
vildagliptine. Daarmee vormt het tevens een rationale voor ontwikkeling van hierop 
gebaseerde, nieuwe geneesmiddelen om vaatcomplicaties bij diabetes te verminderen. 
Als derde hebben we laten zien dat H2S ook fungeert als een anti-oxidant welke 
hersenschade door eiwitaggregaten bij diabetes tegengaat, en dat het CBS-systeem in de 
brein hierbij een belangrijk nieuw doelwit voor therapie zou kunnen vormen. Sowieso 
maken de ogenschijnlijk aan H2S-gerelateerde gunstige effecten in bovenstaande studies 
het H2S(-systeem) als een veelbelovende kandidaat voor therapeutische interventie 
strategieën in het kader van vaat- en orgaanbescherming in diabetes. Of dit ook geldt voor 
het S1P-systeem en fingolimod behoeft meer onderzoek. De gezamenlijke resultaten van 
onze eerdere en huidige studies suggereren echter wel dat dergelijke vervolgonderzoeken 


























Diabetes mellitus (DM) affects the function of blood vessels and various organs, eventually 
leading to life-threatening DM complications. The prediction of diabetic end-organ damage 
and exploring novel treatment strategies herein was the topic of this thesis. We first showed 
that intra-renal small artery function at pre-diabetes predicted an individual’s susceptibility 
to diabetic nephropathy. DM also increases the risk of brain damage and Alzheimer's 
disease via derailment of protein homeostasis. We showed that NaHS - a donor of H2S - is 
a powerful antioxidant compound which attenuated brain protein aggregation DM-rats. The 
results highlight the role of CBS system – which produces H2S in the brain – and the 
potential use of NaHS as a novel strategy against protein aggregation in diabetic brain. 
Anti-diabetic drugs may also exert beneficial effects independent of blood glucose control. 
Employing an animal model of hypertension, we found that metformin and vildagliptin 
both reduced blood pressure and improved vascular function. However, when hypertension 
was combined with insulin-dependent DM the beneficial effects remained after metformin, 
but not vildagliptin. The results suggest superior vascular pleiotropic effects of metformin 
compared to vildagliptin in DM. The immunosuppressant drug and sphingosine 1-
phosphate (S1P) analog fingolimod – used in the treatment of multiple sclerosis - also 
exerts pleiotropic effects on vascular function but the mechanisms involved are relative 
unknown. Our present findings in normal rats now suggest a dual action of fingolimod 
treatment both on vascular smooth muscle and endothelial cell S1P-receptors; how this 
translates in DM conditions remains to be determined. This research may help to identify 
individuals at higher risk of diabetic end-organ damage and provide fuel for novel treatment 

















Diabetes mellitus (DM) veroorzaakt vaatdisfunctie en eind-orgaanschade die uiteindelijk 
kan leiden tot levensbedreigende complicaties. Het voorspellen van die schade en 
verkennen van nieuwe behandelingsstrategieën was onderwerp van dit proefschrift. Als 
eerste vonden we dat individuele functie van kleine intra-renale arteriën voorafgaand aan 
DM voorspellend was voor latere diabetische nierschade. DM verhoogt ook het risico op 
hersenschade en ziekte van Alzheimer door een ontregeling van eiwitaggregatie. Hier 
hebben we laten zien dat NaHS -  een donor van H2S - een sterke antioxidant is en in staat 
eiwitaggregatie in hersenen van DM-ratten te beperken. De resultaten benadrukken een rol 
voor het CBS systeem – producent van H2S in hersenen – en het potentiële gebruik van 
NaHS als een nieuwe strategie tegen eiwitaggregatie in diabetische hersenen. 
Diabetesmedicijnen kunnen soms ook onafhankelijk van beïnvloeding van 
bloedglucosewaarden gunstige effecten bewerkstelligen. Gebruikmakend van een 
diermodel voor hypertensie vonden we dat metformine en vildagliptine beide een 
bloeddrukverlagend en vaatfunctie verbeterend effect hadden. Tijdens hypertensie 
gecombineerd met insuline-afhankelijke-DM bleven deze effecten bestaan na behandeling 
met metformine, maar niet na vildagliptine. Dit suggereert superieure vasculair pleiotrope 
effecten van metformine i.v.t. vildagliptine in DM. Fingolimod -  een immuno-
suppressivum en analoog van sfingosine-1-fosfaat (S1P) – wordt gebruikt bij de 
behandeling van multiple sclerose maar vertoont ook vasculair pleiotrope effecten, al zijn 
de onderliggende werkingsmechanismen hierbij relatief onbekend. Onze huidige 
bevindingen in normale ratten suggereren nu een tweeledige werking van fingolimod 
behandeling op zowel vasculair gladde spiercel als endotheelcel S1P-receptoren; hoe dit zal 
zijn tijdens DM omstandigheden behoeft verder onderzoek. De resultaten in dit proefschrift 
kunnen mogelijk bijdragen aan het identificeren van individuen met verhoogd risico op 


























   
مغز و كليه هستند را تحت تاثير قرار ميدهد. عملكرد اندام هاي زيادي را که شامل عروق خوني،  ٢ديابت نوع 
عوارض طولاني مدت ديابت به صورت آهسته و پيشرونده منجر به آسيب به اين اندام ها مي شود كه در نهايت 
تهديدي براي زندگي به شمار مي آيد. پيش بيني و كنترل عوارض ديابت ميتواند كمك قابل توجهي در برابر صدمه 
اين كتاب ما به بررسي نقش عروق كوچك اندام هايي نظير كليه در  ١ه نمايد. به اين منظور در فصل ناشي از ديابت ب
. در اين بررسي اندوتليوم عروق ميتواند به صورت مثبت پيش بيني پيش بيني گسترش ديابتيك نفروپاتي پرداختيم
عروق به صورت معكوس قابليت اين پيش كننده گسترش ديابتيك نفروپاتي باشند در حالي كه سلول هاي صاف ديواره 
در ارتباط با بررسي عوارض ديابت در توانايي عملكرد ادراكي مغز است. ديابت باعث  ٢فصل بيني را دارند.  
افزايش عدم توازن پروتيين هاي مغز شده و خطر ابتلا به آلزايمر افزايش مي يابد. براي جلوگيري از اين عدم توازن، 
ه عنوان يك انتي اكسيدان موثر مي تواند از آشفتگي پروتيين ها جلوگيري كند و مانع گسترش سولفيد هيدروژن ب
تمركز بر روي بررسي عملكردها و كاربرد هاي جديد و مفيد  ٤عوارض ادراكي ناشي از ديابت گردد. در فصل 
ن است. متفورمين و ديگر داروهاي ضد ديابتي موجود شامل متفورمين و ويلداگلپتين بر روي كاهش فشار خو
ويلداگلپتين هردو منجر به كاهش فشار خون ميشوند، ولي فوايد متفورمين در بهبود وضعيت عملكرد عروق ديابتي 
ما به بررسي عملكردهاي پايه اي عروق پرداختيم كه مي تواند در اينده زيربناي  ٥بهتر از ويلداگلپتين است. در فصل 
باشد. داروی فينگوليمود به عنوان آگونيست گيرنده هاي اسفنگوزين منو فسفات، تحقيقات بيماري هاي عروق ديابتي 
عملكرد دوگانه اي در كاركرد عروق دارد. فينگوليمود، باعث كاهش حساسيت انقباضی سلول هاي ماهيچه اي صاف 
ش توليد مواد جداره عروق درمقابل افزايش فشار داخل عروقي مي شود. از طرف ديگر اندوتليوم عروق با افزاي
افزايش دهنده انقباض عروقي اين كاهش توانايي در انقباض سلول هاي ماهيچه اي صاف جداره عروق در واكنش به 
                                                                                                اسفنگوزين منو فسفات را جبران مي كند.
ته هاي ما كمك بهتری به شناسايي بيماران در معرض خطر ابتلا  به ديابتيك نفروپاتي مي کند. همچنين در نهايت ياف
دارو هايي مانند متفورمين، ويلداگليپتين و سولفيد هيدروژن اثرات مفيد بيشتري در برابر ديابت از آنچه پيشتر تصور 
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